<html lang="en" class="pb-page js" data-request-id="94d671aab38a80fe-LAX"><head data-pb-dropzone="head"><style type="text/css" nonce="94d671aab38a80fe-LAX">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/jaoFk6DW927m2kGE2tPo_NdZidhasod-ZxzJ6HScBFvCqSaXWz1Kll1wynztrphUVVc0xHMefRAQZIE2MV8IdA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d671aab38a80fe-LAX">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.14953981657425996"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Cancer|Leukemia/Lymphoma">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology|Genetics"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2024534","title":"Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers","category":"Research","type":"Original Article","topics":"Cancer|Leukemia/Lymphoma","specialties":"Hematology/Oncology|Genetics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-03-11T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Cancer|Leukemia/Lymphoma\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Genetics\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2024534","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d671aab38a80fe-LAX">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers"><meta name="dc.Creator" content="Eric J. Duncavage"><meta name="dc.Creator" content="Molly C. Schroeder"><meta name="dc.Creator" content="Michele O’Laughlin"><meta name="dc.Creator" content="Roxanne Wilson"><meta name="dc.Creator" content="Sandra MacMillan"><meta name="dc.Creator" content="Andrew Bohannon"><meta name="dc.Creator" content="Scott Kruchowski"><meta name="dc.Creator" content="John Garza"><meta name="dc.Creator" content="Feiyu Du"><meta name="dc.Creator" content="Andrew E.O. Hughes"><meta name="dc.Creator" content="Josh Robinson"><meta name="dc.Creator" content="Emma Hughes"><meta name="dc.Creator" content="Sharon E. Heath"><meta name="dc.Creator" content="Jack D. Baty"><meta name="dc.Creator" content="Julie Neidich"><meta name="dc.Creator" content="Matthew J. Christopher"><meta name="dc.Creator" content="Meagan A. Jacoby"><meta name="dc.Creator" content="Geoffrey L. Uy"><meta name="dc.Creator" content="Robert S. Fulton"><meta name="dc.Creator" content="Christopher A. Miller"><meta name="dc.Creator" content="Jacqueline E. Payton"><meta name="dc.Creator" content="Daniel C. Link"><meta name="dc.Creator" content="Matthew J. Walter"><meta name="dc.Creator" content="Peter Westervelt"><meta name="dc.Creator" content="John F. DiPersio"><meta name="dc.Creator" content="Timothy J. Ley"><meta name="dc.Creator" content="David H. Spencer"><meta name="dc.Description" content="Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential replacement for conven..."><meta name="Description" content="Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential replacement for conven..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-03-11"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2024534"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202103113841010"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2024534"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2024534">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2024534">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2024534">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers | NEJM">
        <meta property="og:title" content="Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2024534">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/1af70c22-5bd4-4565-8207-5f4096dce9b9/nejmoa2024534_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/1af70c22-5bd4-4565-8207-5f4096dce9b9/nejmoa2024534_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Genomic analysis is essential for risk stratification in patients with acute myeloid
leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential
replacement for conven...">
        <meta name="twitter:description" content="Genomic analysis is essential for risk stratification in patients with acute myeloid
leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential
replacement for conven...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2710">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2024534">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2024534">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.384.issue-10;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;article:article:doi\:10.1056/NEJMoa2024534;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024534" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024534" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2024534" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2024534" class="inputDoi"><input type="hidden" value="E.J. Duncavage and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:924-935" class="inputCitation"><input type="hidden" value="03-10-2021" class="inputEPubDate"><input type="hidden" value="March 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d671aab38a80fe-LAX"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Eric J.</span> <span property="familyName">Duncavage</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-5314-3043" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-5314-3043</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Molly C.</span> <span property="familyName">Schroeder</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michele</span> <span property="familyName">O’Laughlin</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roxanne</span> <span property="familyName">Wilson</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandra</span> <span property="familyName">MacMillan</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Bohannon</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Scott</span> <span property="familyName">Kruchowski</span>, <span property="honorificSuffix">B.S.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+19</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Garza</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Feiyu</span> <span property="familyName">Du</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew E.O.</span> <span property="familyName">Hughes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Josh</span> <span property="familyName">Robinson</span>, <span property="honorificSuffix">B.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Emma</span> <span property="familyName">Hughes</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sharon E.</span> <span property="familyName">Heath</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jack D.</span> <span property="familyName">Baty</span>, <span property="honorificSuffix">B.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julie</span> <span property="familyName">Neidich</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matthew J.</span> <span property="familyName">Christopher</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Meagan A.</span> <span property="familyName">Jacoby</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Geoffrey L.</span> <span property="familyName">Uy</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert S.</span> <span property="familyName">Fulton</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher A.</span> <span property="familyName">Miller</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jacqueline E.</span> <span property="familyName">Payton</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel C.</span> <span property="familyName">Link</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matthew J.</span> <span property="familyName">Walter</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Westervelt</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John F.</span> <span property="familyName">DiPersio</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Timothy J.</span> <span property="familyName">Ley</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-9913-0520" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-9913-0520</a></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">David H.</span> <span property="familyName">Spencer</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-19</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">March 10, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">924</span>-<span property="pageEnd">935</span></div><div class="doi">DOI: 10.1056/NEJMoa2024534</div><div class="core-enumeration"><a href="/toc/nejm/384/10"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">10</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DEric%2BJ.%2BDuncavage%252C%2BMolly%2BC.%2BSchroeder%252C%2BMichele%2BO%25E2%2580%2599Laughlin%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2024534%26title%3DGenome%2BSequencing%2Bas%2Ban%2BAlternative%2Bto%2BCytogenetic%2BAnalysis%2Bin%2BMyeloid%2BCancers%26publicationDate%3D03%252F11%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2024534" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DEric%2BJ.%2BDuncavage%252C%2BMolly%2BC.%2BSchroeder%252C%2BMichele%2BO%25E2%2580%2599Laughlin%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D10%26contentID%3D10.1056%252FNEJMoa2024534%26title%3DGenome%2BSequencing%2Bas%2Ban%2BAlternative%2Bto%2BCytogenetic%2BAnalysis%2Bin%2BMyeloid%2BCancers%26publicationDate%3D03%252F11%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ea8f0610-7b75-4e26-b355-ea905c156cd9/nejmoa2024534.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2024534.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024534" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2024534" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024534.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Genomic analysis is essential for risk stratification in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Whole-genome sequencing is a potential replacement for conventional cytogenetic and sequencing approaches, but its accuracy, feasibility, and clinical utility have not been demonstrated.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We used a streamlined whole-genome sequencing approach to obtain genomic profiles for 263 patients with myeloid cancers, including 235 patients who had undergone successful cytogenetic analysis. We adapted sample preparation, sequencing, and analysis to detect mutations for risk stratification using existing European Leukemia Network (ELN) guidelines and to minimize turnaround time. We analyzed the performance of whole-genome sequencing by comparing our results with findings from cytogenetic analysis and targeted sequencing.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Whole-genome sequencing detected all 40 recurrent translocations and 91 copy-number alterations that had been identified by cytogenetic analysis. In addition, we identified new clinically reportable genomic events in 40 of 235 patients (17.0%). Prospective sequencing of samples obtained from 117 consecutive patients was performed in a median of 5 days and provided new genetic information in 29 patients (24.8%), which changed the risk category for 19 patients (16.2%). Standard AML risk groups, as defined by sequencing results instead of cytogenetic analysis, correlated with clinical outcomes. Whole-genome sequencing was also used to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In our study, we found that whole-genome sequencing provided rapid and accurate genomic profiling in patients with AML or MDS. Such sequencing also provided a greater diagnostic yield than conventional cytogenetic analysis and more efficient risk stratification on the basis of standard risk categories. (Funded by the Siteman Cancer Research Fund and others.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Genetic profiling is a routine component of the diagnostic workup for an increasing number of cancers and is used to predict clinical outcomes and responses to targeted therapies. Mutations that are clinically actionable for any individual type of cancer typically span a wide range of genomic events, including chromosomal rearrangements, gene amplifications and deletions, and single-nucleotide changes. The diversity of these findings necessitates the use of multiple platforms to obtain the genetic information needed for clinical management. Whole-genome sequencing is an unbiased method of detecting all types of mutations<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> and could potentially be used to replace current testing algorithms. Such sequencing can also be performed on a limited amount of DNA and can identify genomic changes that may be cryptic in other types of analyses.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup> These features of whole-genome sequencing suggest that it could improve genomic profiling in patients with cancer.</div><div role="paragraph">Genomic abnormalities are particularly important for diagnostic classification and risk assessment in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Recurrent chromosomal abnormalities are the basis for the AML genomic classification system of the World Health Organization, and the association of these alterations and certain genetic mutations with clinical outcomes<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r6 r7" id="body-ref-r7-1" href-manipulated="true">3-7</a></sup> has led to the development of algorithms for genetic risk stratification in patients with AML.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r8" id="body-ref-r8-1" href-manipulated="true">3,8</a></sup> Similar studies involving patients with MDS have resulted in the cytogenetic component of the International Prognostic Scoring System–Revised (IPSS-R) in such patients.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> Although advances in sequencing technology have improved the ability to identify genetic mutations, the detection of chromosomal rearrangements is primarily performed through conventional metaphase cytogenetic analysis (i.e., karyotyping). The latter approach is effective but has several limitations, including the need to obtain viable cells, low sensitivity, and limited resolution. Fluorescence in situ hybridization (FISH) and targeted sequencing assays that use DNA, RNA, or both are also used, but these methods are informative only in the regions selected for analysis and may provide incomplete information regarding identified chromosomal rearrangements. As a result, conventional cytogenetic analysis remains an essential component of the diagnostic workup for patients with AML or MDS.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r8" id="body-ref-r8-2" href-manipulated="true">3,8</a></sup></div><div role="paragraph">The importance of genetic profiling in such patients and the variety of clinically relevant mutation types suggest that whole-genome sequencing could be used in place of standard testing approaches. Although the high cost of sequencing and complex, time-consuming analysis methods have historically restricted such sequencing to research studies,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13 r14 r15 r16" id="body-ref-r16" href-manipulated="true">10-16</a></sup> recent advances have made this analysis simpler to perform, faster, and less expensive. In this study, we developed a streamlined approach to whole-genome sequencing for genomic profiling of patients with AML or MDS and applied it to diagnostic clinical samples in real time to evaluate its feasibility, accuracy, and utility in the clinical setting.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">This study was approved by the institutional review board at Washington University in St. Louis and was conducted in accordance with the provisions of the Declaration of Helsinki. We obtained all the samples that were included in this study from patients with a known or suspected diagnosis of AML or MDS who were seen at the Washington University School of Medicine. All the patients provided written informed consent for genomic sequencing studies. Retrospective samples were obtained from cryopreserved diagnostic bone marrow or peripheral-blood specimens. Prospective samples were obtained from fresh bone marrow aspirate or peripheral-blood specimens collected from consecutive, unselected patients for whom clinical cytogenetic analysis by means of karyotyping had been requested from May 2019 through February 2020.</div></section><section id="sec-1-2"><h3>Conventional Cytogenetic and Molecular Analysis</h3><div role="paragraph">All cytogenetic and FISH analyses were performed in the Cytogenomics and Molecular Pathology Laboratory at the Washington University School of Medicine according to standard clinical protocols. We obtained data regarding genetic mutations as part of standard diagnostic testing using polymerase-chain-reaction (PCR)–based assays for the internal tandem duplication mutation in <i>FLT3</i> (<i>FLT3</i>-ITD) and the <i>NPM1c</i> mutation, a laboratory-developed clinical sequencing assay, or both. (Details regarding the genetic mutations is provided in the <a href="#ap1">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.) Cytogenetic and molecular results were used to assign patients to established European Leukemia Network (ELN) or IPSS-R risk categories.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r9" id="body-ref-r9-2" href-manipulated="true">3,9</a></sup></div></section><section id="sec-1-3"><h3>Genome Sequencing</h3><div role="paragraph">We processed samples and performed sequencing to a target coverage depth of 60× in the Clinical Sequencing Laboratory at the McDonnell Genome Institute of Washington University in St. Louis, a laboratory that has been licensed according to the Clinical Laboratory Improvement Amendments of 1988. This analysis involved the identification of mutations in 40 genes,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> genomewide copy-number alterations greater than 5 Mbp, and structural variants matching 612 recurrent structural alterations in myeloid cancers. (Details regarding genetic identification and structural variants are provided in Tables S1 and S2 in the <a href="#ap1">Supplementary Appendix</a>.) We used the results of whole-genome sequencing to assign patients to a genetic risk group through the same classification systems that are used for conventional analyses.</div></section><section id="sec-1-4"><h3>Confirmatory Studies</h3><div role="paragraph">We used FISH, PCR, chromosomal microarray analyses, and RNA-sequencing data to confirm findings on whole-genome sequencing that had not been detected by cytogenetic analysis. We used standard protocols to perform chromosomal microarray analysis in the Washington University Cytogenetics Core. In the PCR-confirmation analyses, we used primers designed to detect structural variant breakpoints. The methods that were used in RNA sequencing for structural variants have been reported previously.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup></div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">In the time-to-event survival analysis involving study patients with AML, we used death as the end point for the Kaplan–Meier analysis or Cox proportional-hazards regression to test for equal survival across genetic risk groups. Additional details regarding the methods that were used in the statistical analysis are described in the <a href="#ap1">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Streamlined Approach to Whole-Genome Sequencing</h3><div role="paragraph">We developed a streamlined approach to whole-genome sequencing (ChromoSeq) that was designed to provide comprehensive genomic profiling of clinically relevant mutations in samples obtained from patients with AML or MDS, while minimizing the turnaround time and technical complexity (<a href="#f1">Figure 1A</a>). In this approach, we used scalable methods of sample preparation that can be performed by a single technician in less than 8 hours with commercially available reagents, followed by standard high-throughput sequencing. Automated tumor-only variant analysis detected mutations in selected genes, copy-number alterations of more than 5 Mbp, and recurrent structural variants<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19" href-manipulated="true">18,19</a></sup> (Tables S1 and S2). We then summarized these findings in a concise clinical report (Fig. S1A and S1B).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f1.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/1af70c22-5bd4-4565-8207-5f4096dce9b9/assets/images/large/nejmoa2024534_f1.jpg" height="2710" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Timeline of Whole-Genome Sequencing (WGS) Process and Study Design.</div><div class="notes"><div role="doc-footnote">Panel A shows the workflow and approximate processing time for each step of the rapid WGS method used for samples obtained from the study patients. As the first step in library construction, unfragmented DNA is cleaved and tagged for analysis in a process called tagmentation. Examples of the reports that were generated by this process are provided in Figures S1A and S1B in the <a href="#ap1">Supplementary Appendix</a>. Panel B shows the design of the study involving both retrospective and prospective cohorts of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The retrospective cohort included 146 samples obtained from individual patients selected to represent a broad range of cytogenetic and molecular features of AML and MDS. The prospective cohort included 117 unselected, consecutive samples obtained from patients with a known or suspected myeloid cancer for whom cytogenetic testing was requested at the study center. Seven of these patients ultimately received a diagnosis other than AML or MDS. QC denotes quality control.</div></div></figcaption></figure></div><div role="paragraph">We performed a head-to-head comparison of this approach with conventional cytogenetic analysis and targeted sequencing using 235 samples obtained from patients with a known or suspected hematologic cancer who had undergone successful cytogenetic analysis (<a href="#t1">Table 1</a>, <a href="#f1">Figure 1B</a>, and Table S3). This sequencing analysis yielded a mean genome coverage of 50×; a mean of 5.1 clinically relevant mutations (range, 0 to 20) were detected per patient across all variant types (Fig. S1C and S1D). The sensitivity of whole-genome sequencing for recurrent translocations that had been reported on cytogenetic analysis was 100% (40 of 40 samples) (<a href="#f2">Figure 2A</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f2.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/4df34424-43c7-4f02-86e4-27bb92eb1b69/assets/images/large/nejmoa2024534_f2.jpg" height="1264" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">A Comparison of WGS with Conventional Cytogenetic Analysis and Targeted Gene Sequencing.</div><div class="notes"><div role="doc-footnote">Panel A shows the sensitivity of WGS for the detection of recurrent structural variants (SVs) and copy-number alterations (CNAs) as compared with conventional cytogenetic analysis and for the detection of single-nucleotide variants (SNVs) and insertion–deletions (INDELs) as compared with high-coverage targeted gene sequencing. 𝙸 bars denote 95% confidence intervals. Panel B shows the identification and confirmation by WGS of 13 new recurrent SVs that were not detected by conventional cytogenetic analysis, as supported by orthogonal methods, including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) with sequencing of SV breakpoints, or detection of fusion transcripts in RNA-sequence (RNA-seq) data. Panel C shows the identification of 21 new CNAs in 14 patients; 12 of these alterations were confirmed by chromosomal microarray (CMA), FISH, or sequence-defined breakpoints. An additional 9 CNAs were identified by WGS only and could not be confirmed by CMA (in 6 patients) or confirmation was not attempted because of the size or abundance of the CNA event (in 3 patients). CNAs were also identified in 13 patients with ambiguous or inconclusive results on cytogenetic analysis. Additional details regarding these comparisons are provided in Tables S4 and S5 and Figure S2C in the <a href="#ap1">Supplementary Appendix</a>.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/1131647a-f938-4b9c-b31f-1966daa001c8/assets/images/large/nejmoa2024534_t1.jpg" height="3438" width="1652" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Retrospective Cohort</th><th class="txxr-borders">Prospective Cohort</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>All study patients</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">No. of patients</td><td class="xxxx-borders">146</td><td class="xxxr-borders">117</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients with successful cytogenetic analysis<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">126</td><td class="xxxr-borders shading">109</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Patients with AML</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">107</td><td class="xxxr-borders shading">68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean age — yr</td><td class="xxxx-borders">53.7</td><td class="xxxr-borders">60.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">47 (44)</td><td class="xxxr-borders shading">30 (44)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">ELN genetic risk group — no. of patients<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Acute promyelocytic leukemia with t(15;17)(q22;q21)/<i>PML–RARA</i></td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Favorable risk</td><td class="xxxx-borders">28</td><td class="xxxr-borders">19</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">t(8;21)(q22;q22.1)/<i>RUNX1–RUNX1T1</i></td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/<i>CBFB–MYH11</i></td><td class="xxxx-borders">11</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>NPM1c</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD<sup>low</sup><a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">15</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Biallelic <i>CEBPA</i></td><td class="xxxx-borders">3</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Intermediate risk</td><td class="xxxx-borders shading">22</td><td class="xxxr-borders shading">10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">t(9;11)(p21;q23)/<i>KMT2A–MLLT3</i></td><td class="xxxx-borders">1</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wild-type <i>NPM1</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD<sup>low</sup><a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">11</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left"><i>NPM1c</i> with <i>FLT3</i>-ITD or <i>FLT3</i>-ITD<sup>high</sup><a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other risk not favorable or adverse</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Adverse</td><td class="xxxx-borders">20</td><td class="xxxr-borders">27</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Complex karyotype or mutated <i>TP53</i></td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">t(v;11q23.3)/<i>KMT2A</i> rearranged</td><td class="xxxx-borders">3</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">inv(3)(q21.3q26.2) or t(3;3)(q21.3;26.2)/<i>GATA2–MECOM</i></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Chromosome 5 deletion, del(5q), or chromosome 7 deletion</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wild-type <i>NPM1</i> with <i>FLT3</i>-ITD or <i>FLT3</i>-ITD<sup>high</sup><a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Mutated <i>RUNX1</i> or <i>ASXL1</i></td><td class="xxxx-borders">0</td><td class="xxxr-borders">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Undetermined<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">32</td><td class="xxxr-borders shading">7</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Patients with MDS</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">39</td><td class="xxxr-borders shading">42</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean age — yr</td><td class="xxxx-borders">59.8</td><td class="xxxr-borders">68.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">17 (44)</td><td class="xxxr-borders shading">12 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">IPSS-R risk category — no. of patients<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very good</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Good</td><td class="xxxx-borders">11</td><td class="xxxr-borders">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">10</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Poor</td><td class="xxxx-borders">4</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very poor</td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Undetermined<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxr-borders">9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left"><b>Patients with other hematologic cancer</b><a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Acute lymphoblastic leukemia</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03 shading" data-xml-align="left">Other form</td><td class="xbxx-borders shading">NA</td><td class="xbxr-borders shading">2</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Study Patients.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">AML denotes acute myeloid leukemia, MDS myelodysplastic syndromes, and NA not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Successful cytogenetic analysis was defined as the analysis of at least three metaphase cells from cultures prepared from tumor specimens with the use of conventional cytogenetic methods.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Risk groups for patients with AML according to the European Leukemia Network (ELN) guidelines are listed by their defining features and were assigned on the basis of results from conventional cytogenetic analysis; results from FISH (performed at diagnosis) for <i>PML–RARA</i>, <i>CBFB–MYH11</i>, <i>RUNX1–RUNX1T1</i>, del(5q), and chromosome 7; results from polymerase chain reaction (PCR) for <i>FLT3</i>-ITD; and results from targeted sequencing. At least 20 metaphase cells were required to identify a normal karyotype. Nine patients with AML were assigned to a risk group on the basis of positive results on FISH for either <i>PML–RARA</i> (1 patient), <i>CBFB–MYH11</i> (4 patients), or del(5q) (4 patients). Three patients were classified as having intermediate risk on the basis of cytogenetic analysis and testing for <i>NPM1c</i> and <i>FLT3</i>-ITD alone because targeted gene sequencing was not performed.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph"><i>FLT3</i>-ITD status was obtained from clinical testing by means of PCR and capillary electrophoresis. High and low allele ratios were determined on the basis of the established cutoff of 0.5 when available (in 7 of 30 patients with positive results for <i>FLT3</i>-ITD); otherwise <i>FLT3</i>-ITD status was treated as a binary variable.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">The category of undetermined risk indicates that risk could not be classified because of inconclusive or unsuccessful results on cytogenetic analysis (i.e., no metaphase cells were available for analysis or a normal karyotype was observed in &lt;20 cells), as described previously.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Risk categories are those used in the International Prognostic Scoring System–Revised (IPSS-R). The retrospective cohort also included 2 patients with a t(6;9) translocation, which is risk-defining in AML but has no prognostic significance in MDS. Details are provided in Table S3 in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Whole-genome sequencing was performed on samples obtained from consecutive patients, some of whom subsequently received a diagnosis other than AML or MDS, including acute lymphoblastic leukemia, paroxysmal nocturnal hemoglobinuria, and no pathological diagnosis. Three of the patients with acute lymphoblastic leukemia had positive results for <i>BCR–ABL1</i>, which was detected by whole-genome sequencing.</div></div></div></figcaption></figure></div><div role="paragraph">Whole-genome sequencing identified cytogenetically cryptic structural variants in 13 patients, including complex or cryptic chromosomal translocations involving the inv(16)(p13.1q22) fusion gene <i>CBFB–MYH11</i> in 2 patients, the t(7;21)(p22;q22) fusion gene <i>USP42–RUNX1</i> in 1 patient, and 10 rearrangements involving <i>KMT2A</i>, all of which were verified with the use of orthogonal methods (<a href="#f2">Figure 2B</a> and Fig. S2A, Table S4, and Section 1.5 in the <a href="#ap1">Supplementary Appendix</a>). Whole-genome sequencing detected 100% (91 of 91) of the clonal copy-number alterations that had been detected on cytogenetic analysis among the 143 patients in whom conclusive and unambiguous results had been identified by karyotyping (<a href="#f2">Figure 2A</a>). In addition, sequencing identified 21 new copy-number alterations in 14 of these patients, 12 of which were confirmed by other methods (<a href="#f2">Figure 2C</a>, Table S5, and Fig. S2B). The remaining 9 new copy-number alterations showed altered coverage patterns on whole-genome sequencing but could not be confirmed by orthogonal methods because of their small size, low abundance, or both (<a href="#f2">Figure 2C</a>, Fig. S2C, and Table S5). Whole-genome sequencing also provided definitive identification of copy-number alterations in an additional 13 patients with ambiguous or inconclusive results by cytogenetic analysis (Table S5). When we combined these results with the findings in 14 patients who had conclusive results by cytogenetic analysis and newly identified copy-number alterations, plus the findings in 13 patients who were identified as having new structural variants, we determined that 40 of 235 patients (17.0%) had results that had not been detected by conventional cytogenetic analysis.</div><div role="paragraph">In a comparison of genetic mutations that were identified on whole-genome sequencing with those that were identified on high-coverage (&gt;500×) targeted clinical sequencing involving 102 patients, we found sensitivities of 84.6% for single-nucleotide variants and 91.5% for insertion–deletion (indel) mutations, along with a positive predictive value of more than 99% for variants with a minimum variant allele fraction of 5% (<a href="#f2">Figure 2A</a> and Table S6). Similar performance was observed when considering only mutations in genes necessary for risk stratification in patients with AML, including a combined sensitivity of 87.5% for single-nucleotide variants and indels in <i>ASXL1</i>, <i>CEBPA</i>, <i>FLT3</i>, <i>NPM1</i>, <i>RUNX1</i>, and <i>TP53</i> (Fig. S2D and S2E). False negatives occurred either because the variants were in subclones or were at low coverage positions on whole-genome sequencing (Fig. S2F and S2G); such variants were more readily detected with higher coverage sequencing (Fig. S2H).<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup></div></section><section id="sec-2-2"><h3>Clinical Feasibility and Diagnostic Yield</h3><div role="paragraph">We evaluated the feasibility of using whole-genome sequencing for routine clinical testing by prospectively sequencing samples obtained from 117 consecutive patients (Table S7). For this cohort, whole-genome sequencing was performed in weekly batches with a median batch size of 4 (range, 1 to 11) with the use of bone marrow aspirate samples submitted for karyotyping and FISH studies from April 2019 through February 2020. The median total processing time was 5.1 days, which included 2 days for library preparation, 2 days for sequencing, and less than 1 day for analysis (<a href="#f3">Figure 3A</a>). The shortest times were about 3 days (approximately 78 hours), when clinical laboratory staffing allowed samples to be sequenced in dedicated sequencing runs immediately after library generation. Sequencing was successful in all the samples, and only 5 samples (4.3%) had less than 25× genome coverage in a single assay run. Seven samples required manual review of the automated copy-number alteration calls, with the remaining 110 samples (94.0%) needing no additional interventions to finalize the sequencing report.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f3.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/83425336-c206-4394-88ac-99d8c6bc8fde/assets/images/large/nejmoa2024534_f3.jpg" height="2649" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Clinical Feasibility and Diagnostic Yield of WGS-Based Genomic Profiling in 117 Consecutive Patients.</div><div class="notes"><div role="doc-footnote">Panel A shows the time it took to process samples obtained from 117 consecutive patients with AML or MDS by means of WGS from April 2019 through February 2020. The median processing time for all study patients is indicated by the dashed horizontal black line. The height of each bar shows the total time in days for processing, starting from construction of the sequencing library and ending with completion of the automated final report for an individual patient sample. The duration of each individual step (as obtained from time stamps recorded in the information management system of the clinical laboratory) is indicated by the shaded bar segments and includes the duration of library generation and quality assessment, sequencing, and analysis and reporting. These times reflect the processing time plus waiting time before the next step. Longer turnaround times occurred because of delays between steps, rather than longer processing times. The dashed horizontal red lines show the recommended maximum turnaround time for FISH testing and conventional cytogenetic analysis, according to published recommendations,<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-1" href-manipulated="true" aria-label="Reference 21">21</a></sup> although shorter turnaround times occur in many laboratories.</div><div role="doc-footnote">Panel B shows the yield of new WGS findings in samples obtained from 68 unselected, consecutive patients with AML. The top panel shows the cumulative number of patients with new genomic findings that were identified by WGS, as compared with conventional cytogenetic analysis or FISH, performed at the time of diagnosis, along with the cumulative number of patients with new events that changed the category of genetic risk group on the basis of established European Leukemia Network (ELN) guidelines.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-5" href-manipulated="true" aria-label="Reference 3">3</a></sup> FISH testing included assays for <i>PML–RARA</i>, <i>CBFB–MYH11</i>, <i>RUNX1–RUNX1T1</i>, del(5q), and chromosome 7 deletion, according to recommendations<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r21" id="body-ref-r21-2" href-manipulated="true">3,21</a></sup>; all testing was performed in samples obtained from 60 of 68 patients (88%), and subgroups of these assays were performed for the remaining patients. The results of ELN assignments to a genetic risk group by WGS, conventional cytogenetic analysis with FISH, and cytogenetic analysis alone are shown in the middle panel. The red asterisk indicates that the patient’s risk group was reclassified according to the WGS results, and the red arrow indicates that the conventional risk-group assignment was based on FISH results alone. Genomic events that were detected by WGS are shown in the bottom panel and are labeled as concordant with cytogenetic analysis, FISH, or target sequencing (in black), new findings made by WGS (in blue), and new findings that resulted in a change in the ELN genetic risk group (in red). The status regarding internal tandem duplication in <i>FLT3</i> (<i>FLT3</i>-ITD) and the allele ratio as determined by PCR were used for both conventional and WGS-based risk stratifications.</div></div></figcaption></figure></div><div role="paragraph">This set of consecutive patients was also evaluated to estimate the diagnostic yield from whole-genome sequencing as compared with testing with cytogenetic analysis and targeted sequencing. This analysis was performed separately in samples obtained from patients with AML and in those obtained from patients with MDS. (Seven patients with other diagnoses were excluded from this analysis.) In the AML samples, the comparisons included clinical results from a standard FISH panel<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r21" id="body-ref-r21-3" href-manipulated="true">3,21</a></sup> along with cytogenetic analysis and targeted sequencing to provide a realistic estimate of the expected yield of whole-genome sequencing. In this prospective cohort, results from conventional cytogenetic analysis and FISH assays in the 68 patients with AML resulted in the diagnosis of acute promyelocytic leukemia with the fusion gene PML–RARA in 5 patients and in the assignment of 27 patients to the adverse-risk group, 10 to the intermediate-risk group, and 19 to the favorable-risk group on the basis of established guidelines<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r8" id="body-ref-r8-3" href-manipulated="true">3,8</a></sup>; 7 patients had unsuccessful or inconclusive results on cytogenetic analysis and could not be assigned to a risk group (Table S7). Four patients were assigned to risk groups solely on the basis of positive FISH results for either <i>PML–RARA</i> (1 patient) or del(5q) (3 patients) (<a href="#f3">Figure 3B</a>).</div><div role="paragraph">Whole-genome sequencing that was performed on samples obtained from the same cohort identified new abnormalities that were not present in the karyotype analysis or reported by FISH in 17 of 68 patients (25%). These abnormalities included cryptic or complex chromosomal rearrangements in 5 patients, new copy-number alterations that resulted in a complex karyotype in 4 patients, and identification of either a normal karyotype (in 4 patients) or 1 or 2 cytogenetic abnormalities in patients with inconclusive or unsuccessful results by cytogenetic analysis (in 4 patients) (Table S8). Using data only from whole-genome sequencing and a PCR assay for <i>FLT3</i>-ITD, we reclassified 10 of 68 patients (15%) without acute promyelocytic leukemia to a risk group that differed from the one that was based on conventional testing (Fig. S3A). A similar yield was observed for the 42 prospective patients with MDS; of these patients, 12 (29%) had inconclusive results on cytogenetic analysis or new findings on whole-genome sequencing and 9 (21%) were assigned to a new IPSS-R risk category (Fig. S3B and Tables S7 and S8). These findings bring the combined number of patients with a reclassified risk-group assignment to 19 of all 117 patients (16.2%) who were included in this prospective cohort.</div></section><section id="sec-2-3"><h3>Predictive Value Using Existing Genetic-Risk Categories</h3><div role="paragraph">We next asked whether whole-genome sequencing could be used in place of cytogenetic analysis to predict clinical outcomes using existing genetic risk groups. To avoid the confounding effect of hematopoietic stem-cell transplantation on outcome, we focused our analysis on 71 patients with AML who did not undergo this procedure, including 41 prospective and 30 retrospective patients; 58 patients (82%) received intensive induction chemotherapy, whereas the remaining 13 were treated with hypomethylating agents. These patients were assigned to a genetic risk group on the basis of whole-genome sequencing alone or conventional testing (the combined results of cytogenetic analysis, clinical FISH results, and targeted sequencing). The <i>FLT3</i>-ITD mutational status that was based on a PCR assay was used in both these classifications.</div><div role="paragraph">Risk-group assignments that were based on conventional testing were in agreement with the results from whole-genome sequencing for 63 of 71 patients (89%); 8 patients were reassigned to a different risk category, including 5 who had new adverse-risk findings that were identified by whole-genome sequencing (Table S9 and Fig. S4A). Risk groups that were defined according to the two methods had the expected associations with overall survival (adjusted P=0.09 by log-rank test in groups identified by conventional testing; adjusted P=0.01 by log-rank test in groups identified by whole-genome sequencing) (<a href="#f4">Figure 4A and 4B</a>). Whole-genome sequencing provided slightly better identification of patients with adverse risk and poor outcomes than conventional testing, with a hazard ratio for death of 0.32 (95% confidence interval [CI], 0.11 to 0.92) on age-adjusted Cox regression analysis, as compared with a hazard ratio of 0.66 (95% CI, 0.17 to 1.05) by conventional risk-group analysis. Similar results were observed in a larger cohort of 101 patients who were treated with either consolidation chemotherapy or stem-cell transplantation (Table S9 and Fig. S4B and S4C).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 4</div><nav><a href="#f4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f4" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f4" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f4.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/a1337548-516d-4a33-91f6-ab0ca3649090/assets/images/large/nejmoa2024534_f4.jpg" height="2244" width="2640" aria-labelledby="f4" loading="lazy"></a><figcaption><div class="caption">Risk Assessment by WGS in Patients with AML, According to Existing Genetic Risk Groups.</div><div class="notes"><div role="doc-footnote">Panel A shows overall survival for 71 patients with AML who were treated with chemotherapy alone after remission, as stratified into established ELN genetic risk groups<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-9" href-manipulated="true" aria-label="Reference 3">3</a></sup> on the basis of a combination of conventional cytogenetic analysis, FISH, and targeted gene sequencing. Panel B shows the same cohort as in Panel A with risk stratification according to WGS results. The ratio of the mutated <i>FLT3</i>-ITD allele to the wild-type allele, as determined by PCR, was used for both the conventional and WGS classifications; the presence or absence of the mutation was used when allele ratios were not available. Panel C shows the clinical outcomes for 27 patients for whom genetic risk could not be determined because of inconclusive, unsuccessful, or unknown results on cytogenetic analysis. The median survival in this cohort was 11.2 months (95% confidence interval [CI], 5.6 to 38.8). Panel D shows the stratification of the cohort in Panel C into established genetic risk groups with the use of WGS results, which predicted shorter overall survival for patients at adverse risk than for those at intermediate or favorable risk (not adverse) (age-adjusted hazard ratio for death for intermediate or favorable risk versus adverse risk, 0.29; 95% CI, 0.09 to 0.94). All P values were calculated with the use of a log-rank test for equal survival among the groups and were adjusted for multiple comparisons.</div></div></figcaption></figure></div><div role="paragraph">We reasoned that whole-genome sequencing could have the greatest benefit for patients for whom cytogenetic results are unavailable at diagnosis, which occurs in up to 20% of patients with AML.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r22 r23 r24" id="body-ref-r24" href-manipulated="true">7,22–24</a></sup> Thus, we used whole-genome sequencing to evaluate 27 patients with AML who were not treated with stem-cell transplantation (of whom 22 received standard induction chemotherapy), who could not be assigned to a risk group at the time of diagnosis because of unsuccessful cytogenetic analysis (in 6 patients), inconclusive results (in 13), or unknown results (in 8), and who had no reports of risk-defining events by FISH (Table S10). The mean age at diagnosis in this cohort was similar to that of patients with defined cytogenetic risk (60.8 years and 54.7 years, respectively), and the median overall survival was 11.2 months (95% CI, 5.6 to 38.8) (<a href="#f4">Figure 4C</a>). In this cohort, whole-genome sequencing identified risk-defining chromosomal abnormalities in 4 patients, including <i>KMT2A</i> and <i>RUNX1–RUNXT1</i> rearrangements in 1 patient each or a complex karyotype in 2 patients; the remaining 23 patients had either a normal karyotype or one or two abnormalities and were assigned to a risk category on the basis of mutations identified by whole-genome sequencing (Table S10 and Fig. S4D).</div><div role="paragraph">Survival analysis of these patients showed that risk predictions that were based on whole-genome sequencing also correlated with outcomes, with significantly longer overall survival in 21 patients with intermediate or favorable risk (median survival, 20.5 months; 95% CI, 5.6 to 38.8) than in 6 patients with adverse risk (median survival, 3.3 months; 95% CI, 1.7 to 18.9; adjusted P=0.03 by log-rank test) (<a href="#f4">Figure 4D</a>); hazard ratio of 0.29 (95% CI, 0.09 to 0.94) by age-adjusted Cox regression analysis. This survival difference was superior to that resulting from the assignment of patients to risk groups on the basis of gene mutations alone (Fig. S4E) and was maintained when 11 additional patients with inconclusive results on cytogenetic analysis who underwent allogeneic stem-cell transplantation were included in this cohort (total of 38 patients) (Table S10 and Fig. S4F).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this study, we demonstrated the clinical utility of whole-genome sequencing for the genomic evaluation of patients with AML or MDS. Results from 263 patients showed that such sequencing was equivalent to or better than conventional testing, both in analytical performance and clinical applicability. Whole-genome sequencing detected 100% of the clinically significant abnormalities that had been identified by cytogenetic analysis and clinical FISH assays. In addition, sequencing provided new genetic information in 25% of patients, more than half of whom would have been assigned to a different genetic risk category with results from conventional testing. In practice, the diagnostic yield of whole-genome sequencing will depend on laboratory-specific karyotyping practices and the use of FISH or other ancillary testing; some rapid diagnostic assays may still be required for urgent treatment decisions (e.g., FISH or quantitative PCR for <i>PML–RARA</i> rearrangements and PCR for <i>FLT3</i>-ITD mutations). However, our study shows that whole-genome sequencing can provide definitive results for clinically relevant genomic events with the use of a single test. Prospective real-time sequencing of samples obtained from consecutive patients showed that such sequencing yields complete genomic information in a clinically relevant timeframe. This speed was made possible by faster laboratory methods and automated data analysis that focused on clinically relevant mutations, which allowed us to generate reports in as little as 3 days. We also found that such results can be used for risk predictions with existing, clinically validated risk-stratification systems. Although larger studies involving more patients will be required to firmly establish the clinical performance of whole-genome sequencing, our proof-of-concept study shows that this method has the potential to add prognostic value by expanding risk stratification to more patients, especially for those with inconclusive results on cytogenetic analysis, where whole-genome sequencing could have an immediate effect on treatment decisions.</div><div role="paragraph">We found that the logistical barriers for the genomic profiling of tumors by whole-genome sequencing can essentially be eliminated with the approaches described here. However, an additional (and major) barrier to implementation has been cost. Unlike other clinical assays in which technical labor is a substantial expense, the cost of whole-genome sequencing is driven nearly entirely by the sequencing itself. As a result, the continued decrease in the price of sequencing<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-1" href-manipulated="true" aria-label="Reference 25">25</a></sup> now makes the costs associated with this method similar to those of current testing platforms, which are estimated to range from $1,000 to $2,000 per patient.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> (Details regarding cost comparisons are provided in the <a href="#ap1">Supplementary Appendix</a>.) The current cost of reagents, technical labor, and analysis for whole-genome sequencing with the approach described here is approximately $1,900 on the basis of a list price of approximately $11 to generate 1 billion base pairs of sequence data. In high-volume laboratories where sequencing costs are lower (approximately $7 per Gbp),<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-2" href-manipulated="true" aria-label="Reference 25">25</a></sup> the cost would be about $1,300. Although the actual charge for clinical whole-genome sequencing will probably be higher owing to the additional costs associated with clinical-laboratory implementation, these calculations suggest that this method is likely to reach price parity with standard testing when sequencing falls below $5 per Gbp. Since sequencing data can also provide additional genetic information that is often obtained by means of other genetic assays (e.g., pharmacogenetic testing or HLA typing), price parity for some patients will come even sooner.</div><div role="paragraph">Implementing whole-genome sequencing for clinical testing can provide a unified, stable, and extensible platform that minimizes laboratory-specific bias and that can be standardized throughout the world. Although our study focused on myeloid cancers, many of the advantages of whole-genome sequencing that we observed will directly apply to patients with other cancers. Whole-genome sequencing can be performed on DNA from tissue biopsy samples of solid tumors, which are often insufficient for standard molecular assays and difficult to culture for cytogenetic studies. The benefits could be even greater for these cancer types, in which whole-genome sequencing could be used to rapidly survey the entire genome for an expanding number of key mutations and structural alterations with only a small amount of DNA. Such an approach would simplify genomic testing for these patients and probably increase the yield of clinically relevant findings, which may ultimately improve the precision of approaches for treating many patients with cancer.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was updated on March 18, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap3">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (19-FY19-01) from the Alvin J. Siteman Cancer Research Fund and a grant (3UL1TR002345-02S1) from the <span class="named-content" data-type="funder">National Center for Advancing Translational Sciences</span> (to Drs. Spencer and Duncavage) and by grants (R33CA217700-01, to Drs. Duncavage and Walter, and K08CA190815, to Dr. Spencer) from the National Cancer Institute (<span class="named-content" data-type="funder">NCI</span>). Support for procurement and annotation of human samples was provided by a grant (P01 CA101937, to Dr. Ley) from the Genomics of AML Program Project of the <span class="named-content" data-type="funder">NCI</span> and the Specialized Program of Research Excellence in AML (P50CA171963, to Dr. Link). Core services were provided by the <span class="named-content" data-type="funder">Alvin J. Siteman Cancer Center</span> Tissue Procurement Core and Biostatistics Shared Resource Core through an <span class="named-content" data-type="funder">NCI</span> Cancer Center grant (P30CA091842). Prospective sequencing was supported in part by reagents provided by Illumina.</div><div role="paragraph"><a href="#ap2">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the staff of the Cytogenomics and Molecular Pathology Laboratory, Genome Technology Access Center, and the McDonnell Genome Institute at the Washington University School of Medicine for their contributions to this project.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2024534_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024534/suppl_file/nejmoa2024534_appendix.pdf" download="nejmoa2024534_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024534_appendix.pdf" data-doi="10.1056/NEJMoa2024534">Download</a></li><li>9.10 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2024534_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024534/suppl_file/nejmoa2024534_disclosures.pdf" download="nejmoa2024534_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024534_disclosures.pdf" data-doi="10.1056/NEJMoa2024534">Download</a></li><li>731.76 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2024534_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2024534/suppl_file/nejmoa2024534_data-sharing.pdf" download="nejmoa2024534_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2024534_data-sharing.pdf" data-doi="10.1056/NEJMoa2024534">Download</a></li><li>68.06 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Nangalia J, Campbell PJ. Genome sequencing during a patient’s journey through cancer. <em>N Engl J Med</em> 2019;381:2145-2156.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMra1910138&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31774959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000501362000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genome+sequencing+during+a+patient%E2%80%99s+journey+through+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2145-2156&amp;doi=10.1056%2FNEJMra1910138&amp;pmid=31774959" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. <em>JAMA</em> 2011;305:1577-1584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2011.497" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21505136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000289683000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+whole-genome+sequencing+to+diagnose+a+cryptic+fusion+oncogene.&amp;publication_year=2011&amp;journal=JAMA&amp;pages=1577-1584&amp;doi=10.1001%2Fjama.2011.497&amp;pmid=21505136" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <em>Blood</em> 2017;129:424-447.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-08-733196" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27895058/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396531400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+AML+in+adults%3A+2017+ELN+recommendations+from+an+international+expert+panel.&amp;publication_year=2017&amp;journal=Blood&amp;pages=424-447&amp;doi=10.1182%2Fblood-2016-08-733196&amp;pmid=27895058" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic mutations with clinical outcomes </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] risk stratification in patients with AML. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] workup for patients with AML or MDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Network (ELN) or IPSS-R risk categories. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r3-5"><i aria-hidden="true" class="icon-return"></i><span>e [...] European Leukemia Network (ELN) guidelines. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r3-6"><i aria-hidden="true" class="icon-return"></i><span>f [...] 7 deletion, according to recommendations </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] clinical results from a standard FISH panel </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] on the basis of established guidelines </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f4" role="menuitem" data-target="#fv-body-ref-r3-9"><i aria-hidden="true" class="icon-return"></i><span>i [...] into established ELN genetic risk groups </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <em>N Engl J Med</em> 2008;358:1909-1918.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa074306&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18450602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255387900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=1909-1918&amp;doi=10.1056%2FNEJMoa074306&amp;pmid=18450602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. <em>Blood</em> 2005;106:3733-3739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-06-2248" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16076867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233662400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nucleophosmin+gene+mutations+are+predictors+of+favorable+prognosis+in+acute+myelogenous+leukemia+with+a+normal+karyotype.&amp;publication_year=2005&amp;journal=Blood&amp;pages=3733-3739&amp;doi=10.1182%2Fblood-2005-06-2248&amp;pmid=16076867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. <em>N Engl J Med</em> 2016;375:2023-2036.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1605949&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27959731/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388464300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TP53+and+decitabine+in+acute+myeloid+leukemia+and+myelodysplastic+syndromes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=2023-2036&amp;doi=10.1056%2FNEJMoa1605949&amp;pmid=27959731" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. <em>N Engl J Med</em> 2016;374:2209-2221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1516192&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27276561/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377920500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+classification+and+prognosis+in+acute+myeloid+leukemia.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=2209-2221&amp;doi=10.1056%2FNEJMoa1516192&amp;pmid=27276561" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic mutations with clinical outcomes </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] occurs in up to 20% of patients with AML. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. NCCN guidelines for patients: acute myeloid leukemia (<a href="https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf">https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Comprehensive+Cancer+Network.+NCCN+guidelines+for+patients%3A+acute+myeloid+leukemia+%28https%3A%2F%2Fwww.nccn.org%2Fpatients%2Fguidelines%2Fcontent%2FPDF%2Faml-patient.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk stratification in patients with AML. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] workup for patients with AML or MDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] on the basis of established guidelines </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. <em>Blood</em> 2012;120:2454-2465.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-03-420489" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22740453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309044600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+international+prognostic+scoring+system+for+myelodysplastic+syndromes.&amp;publication_year=2012&amp;journal=Blood&amp;pages=2454-2465&amp;doi=10.1182%2Fblood-2012-03-420489&amp;pmid=22740453" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] System–Revised (IPSS-R) in such patients. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Network (ELN) or IPSS-R risk categories. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. <em>Nature</em> 2008;456:66-72.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature07485" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18987736/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260674000041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+sequencing+of+a+cytogenetically+normal+acute+myeloid+leukaemia+genome.&amp;publication_year=2008&amp;journal=Nature&amp;pages=66-72&amp;doi=10.1038%2Fnature07485&amp;pmid=18987736" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. <em>N Engl J Med</em> 2013;368:2059-2074.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1301689&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23634996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000319574200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+and+epigenomic+landscapes+of+adult+de+novo+acute+myeloid+leukemia.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=2059-2074&amp;doi=10.1056%2FNEJMoa1301689&amp;pmid=23634996" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] such sequencing to research studies, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] variants have been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Mardis ER. The $1,000 genome, the $100,000 analysis? <em>Genome Med</em> 2010;2:84-84.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/gm205" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21114804/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208627100084" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+%241%2C000+genome%2C+the+%24100%2C000+analysis%3F&amp;publication_year=2010&amp;journal=Genome+Med&amp;pages=84-84&amp;doi=10.1186%2Fgm205&amp;pmid=21114804" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. <em>N Engl J Med</em> 2009;361:1058-1066.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa0903840&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19657110/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269659400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recurring+mutations+found+by+sequencing+an+acute+myeloid+leukemia+genome.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=1058-1066&amp;doi=10.1056%2FNEJMoa0903840&amp;pmid=19657110" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. <em>Cell</em> 2012;150:264-278.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2012.06.023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22817890/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306595700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+origin+and+evolution+of+mutations+in+acute+myeloid+leukemia.&amp;publication_year=2012&amp;journal=Cell&amp;pages=264-278&amp;doi=10.1016%2Fj.cell.2012.06.023&amp;pmid=22817890" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. <em>Nat Med</em> 2018;24:103-112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.4439" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29227476/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422965900016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+molecular+landscape+of+pediatric+acute+myeloid+leukemia+reveals+recurrent+structural+alterations+and+age-specific+mutational+interactions.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=103-112&amp;doi=10.1038%2Fnm.4439&amp;pmid=29227476" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Rusch M, Nakitandwe J, Shurtleff S, et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <em>Nat Commun</em> 2018;9:3962-3962.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-018-06485-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30262806/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445820300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+cancer+genomic+profiling+by+three-platform+sequencing+of+whole+genome%2C+whole+exome+and+transcriptome.&amp;publication_year=2018&amp;journal=Nat+Commun&amp;pages=3962-3962&amp;doi=10.1038%2Fs41467-018-06485-7&amp;pmid=30262806" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Duncavage EJ, Jacoby MA, Chang GS, et al. Mutation clearance after transplantation for myelodysplastic syndrome. <em>N Engl J Med</em> 2018;379:1028-1041.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1804714&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30207916/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444501600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutation+clearance+after+transplantation+for+myelodysplastic+syndrome.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1028-1041&amp;doi=10.1056%2FNEJMoa1804714&amp;pmid=30207916" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Huret J-L, Ahmad M, Arsaban M, et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. <em>Nucleic Acids Res</em> 2013;41:(D1):D920-D924.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gks1082" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23161685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000312893300130" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atlas+of+genetics+and+cytogenetics+in+oncology+and+haematology+in+2013.&amp;publication_year=2013&amp;journal=Nucleic+Acids+Res&amp;pages=D920-D924&amp;doi=10.1093%2Fnar%2Fgks1082&amp;pmid=23161685" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <em>Blood</em> 2016;127:2391-2405.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-03-643544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27069254/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378333900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia.&amp;publication_year=2016&amp;journal=Blood&amp;pages=2391-2405&amp;doi=10.1182%2Fblood-2016-03-643544&amp;pmid=27069254" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. <em>Cell Syst</em> 2015;1:210-223.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cels.2015.08.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26645048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209925900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+cancer+genome+sequencing+and+analysis.&amp;publication_year=2015&amp;journal=Cell+Syst&amp;pages=210-223&amp;doi=10.1016%2Fj.cels.2015.08.015&amp;pmid=26645048" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. <em>Leukemia</em> 2019;33:1851-1867.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-019-0378-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30696948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479118400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=European+recommendations+and+quality+assurance+for+cytogenomic+analysis+of+haematological+neoplasms.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=1851-1867&amp;doi=10.1038%2Fs41375-019-0378-z&amp;pmid=30696948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] according to published recommendations, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r21-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] 7 deletion, according to recommendations </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] clinical results from a standard FISH panel </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <em>Blood</em> 2002;100:4325-4336.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2002-03-0772" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12393746/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000179759800015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29.&amp;publication_year=2002&amp;journal=Blood&amp;pages=4325-4336&amp;doi=10.1182%2Fblood-2002-03-0772&amp;pmid=12393746" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Lazarevic V, Hörstedt A-S, Johansson B, et al. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. <em>Eur J Haematol</em> 2015;94:419-423.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/ejh.12446" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25200361/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352633000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Failure+matters%3A+unsuccessful+cytogenetics+and+unperformed+cytogenetics+are+associated+with+a+poor+prognosis+in+a+population-based+series+of+acute+myeloid+leukaemia.&amp;publication_year=2015&amp;journal=Eur+J+Haematol&amp;pages=419-423&amp;doi=10.1111%2Fejh.12446&amp;pmid=25200361" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <em>Br J Haematol</em> 2014;164:245-250.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12625" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24383844/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329178100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Unsuccessful+diagnostic+cytogenetic+analysis+is+a+poor+prognostic+feature+in+acute+myeloid+leukaemia.&amp;publication_year=2014&amp;journal=Br+J+Haematol&amp;pages=245-250&amp;doi=10.1111%2Fbjh.12625&amp;pmid=24383844" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Wetterstrand KA. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). <em>National Human Genome Research Institute</em>, 2020 (<a href="https://www.genome.gov/sequencingcostsdata">www.genome.gov/sequencingcostsdata</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+sequencing+costs%3A+data+from+the+NHGRI+Genome+Sequencing+Program+%28GSP%29.&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] decrease in the price of sequencing </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] costs are lower (approximately $7 per Gbp), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Cressman S, Karsan A, Hogge DE, et al. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <em>Br J Haematol</em> 2016;174:526-535.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.14076" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27098559/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383774500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+impact+of+genomic+diagnostics+for+intermediate-risk+acute+myeloid+leukaemia.&amp;publication_year=2016&amp;journal=Br+J+Haematol&amp;pages=526-535&amp;doi=10.1111%2Fbjh.14076&amp;pmid=27098559" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/10"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">10</span></span> • <span property="datePublished">March 11, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">924</span>-<span property="pageEnd">935</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2024534" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2024534?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: March 10, 2021</div><div><b class="core-label">Published in issue</b>: March 11, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/cancer" alt="View article keyword Cancer" data-interactiontype="article_recirculation_click">Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/leukemia-lymphoma" alt="View article keyword Leukemia/Lymphoma" data-interactiontype="article_recirculation_click">Leukemia/Lymphoma</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Eric J.</span> <span property="familyName">Duncavage</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-5314-3043" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-5314-3043</a></span>, <span property="author" typeof="Person"><span property="givenName">Molly C.</span> <span property="familyName">Schroeder</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michele</span> <span property="familyName">O’Laughlin</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roxanne</span> <span property="familyName">Wilson</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandra</span> <span property="familyName">MacMillan</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Bohannon</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Scott</span> <span property="familyName">Kruchowski</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Garza</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Feiyu</span> <span property="familyName">Du</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew E.O.</span> <span property="familyName">Hughes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Josh</span> <span property="familyName">Robinson</span>, <span property="honorificSuffix">B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Emma</span> <span property="familyName">Hughes</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sharon E.</span> <span property="familyName">Heath</span></span>, <span property="author" typeof="Person"><span property="givenName">Jack D.</span> <span property="familyName">Baty</span>, <span property="honorificSuffix">B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julie</span> <span property="familyName">Neidich</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matthew J.</span> <span property="familyName">Christopher</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Meagan A.</span> <span property="familyName">Jacoby</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Geoffrey L.</span> <span property="familyName">Uy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert S.</span> <span property="familyName">Fulton</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christopher A.</span> <span property="familyName">Miller</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jacqueline E.</span> <span property="familyName">Payton</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel C.</span> <span property="familyName">Link</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matthew J.</span> <span property="familyName">Walter</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Westervelt</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John F.</span> <span property="familyName">DiPersio</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Timothy J.</span> <span property="familyName">Ley</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-9913-0520" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-9913-0520</a></span>, and <span property="author" typeof="Person"><span property="givenName">David H.</span> <span property="familyName">Spencer</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Pathology and Immunology (E.J.D., M.C.S., A.E.O.H., J.N., J.E.P., D.H.S.), McDonnell Genome Institute (M.O., R.W., S.M., A.B., S.K., J.G., F.D., R.S.F., D.H.S.), and the Divisions of Oncology (J.R., E.H., S.E.H., M.J.C., M.A.J., G.L.U., C.A.M., D.C.L., M.J.W., P.W., J.F.D., T.J.L., D.H.S.) and Biostatistics (J.D.B.), Department of Medicine, Washington University School of Medicine, St. Louis.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Spencer at the Division of Oncology, Department of Medicine, Washington University School of Medicine, Campus Box 8007, 660 South Euclid Ave., St. Louis, MO 63110, or at <a href="mailto:dspencer@wustl.edu">dspencer@wustl.edu</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">195</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2024534" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="4170a2b8-b7be-a524-1701-e956b94c5203"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943" style="display:inline-block;">
                <img alt="Article has an altmetric score of 313" src="https://badges.altmetric.com/?size=320&amp;score=313&amp;types=mbtttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_4170a2b8-b7be-a524-1701-e956b94c5203" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943&amp;tab=news">
          Picked up by <b>24</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943&amp;tab=twitter">
          Posted by <b>225</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=101653943&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>304</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d671aab38a80fe-LAX"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2024534"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2024534%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="195" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jenny M. Ho, </li><li class="list-inline-item cited-by__entry__author">Uday Deotare, </li><li class="list-inline-item cited-by__entry__author">Aatif Qureshi, </li><li class="list-inline-item cited-by__entry__author">Laila Schenkel, </li><li class="list-inline-item cited-by__entry__author">Benjamin Chin-Yee, </li><li class="list-inline-item cited-by__entry__author">Anahita Mohseni Meybodi, </li><li class="list-inline-item cited-by__entry__author">Emilie Lalonde, </li><li class="list-inline-item cited-by__entry__author">Lalit Saini, </li><li class="list-inline-item cited-by__entry__author">Alan Gob, </li><li class="list-inline-item cited-by__entry__author">Selay Lam, </li><li class="list-inline-item cited-by__entry__author">Cyrus Hsia, </li><li class="list-inline-item cited-by__entry__author">Bekim Sadikovic, </li><li class="list-inline-item cited-by__entry__author">Benjamin Hedley, </li><li class="list-inline-item cited-by__entry__author">Ian Chin-Yee, </li></ul><span class="cited-by__entry__title">Patient-Centered Genomic Diagnostic Testing for AML: A Quality Improvement Project, </span><span class="cited-by__entry__series-title">JCO Oncology Practice, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/OP-24-00776" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/OP-24-00776</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/OP-24-00776" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jean-Baptiste Alberge, </li><li class="list-inline-item cited-by__entry__author">Ankit K. Dutta, </li><li class="list-inline-item cited-by__entry__author">Andrea Poletti, </li><li class="list-inline-item cited-by__entry__author">Tim H. H. Coorens, </li><li class="list-inline-item cited-by__entry__author">Elizabeth D. Lightbody, </li><li class="list-inline-item cited-by__entry__author">Rosa Toenges, </li><li class="list-inline-item cited-by__entry__author">Xavi Loinaz, </li><li class="list-inline-item cited-by__entry__author">Sofia Wallin, </li><li class="list-inline-item cited-by__entry__author">Andrew Dunford, </li><li class="list-inline-item cited-by__entry__author">Oliver Priebe, </li><li class="list-inline-item cited-by__entry__author">Johnathan Dagan, </li><li class="list-inline-item cited-by__entry__author">Cody J. Boehner, </li><li class="list-inline-item cited-by__entry__author">Erica Horowitz, </li><li class="list-inline-item cited-by__entry__author">Nang K. Su, </li><li class="list-inline-item cited-by__entry__author">Hadley Barr, </li><li class="list-inline-item cited-by__entry__author">Laura Hevenor, </li><li class="list-inline-item cited-by__entry__author">Katherine Towle, </li><li class="list-inline-item cited-by__entry__author">Rashmika Beesam, </li><li class="list-inline-item cited-by__entry__author">Jenna B. Beckwith, </li><li class="list-inline-item cited-by__entry__author">Jacqueline Perry, </li><li class="list-inline-item cited-by__entry__author">David M. Cordas dos Santos, </li><li class="list-inline-item cited-by__entry__author">Luca Bertamini, </li><li class="list-inline-item cited-by__entry__author">Patricia T. Greipp, </li><li class="list-inline-item cited-by__entry__author">Kirsten Kübler, </li><li class="list-inline-item cited-by__entry__author">Peter F. Arndt, </li><li class="list-inline-item cited-by__entry__author">Carolina Terragna, </li><li class="list-inline-item cited-by__entry__author">Elena Zamagni, </li><li class="list-inline-item cited-by__entry__author">Eileen M. Boyle, </li><li class="list-inline-item cited-by__entry__author">Kwee Yong, </li><li class="list-inline-item cited-by__entry__author">Gareth Morgan, </li><li class="list-inline-item cited-by__entry__author">Brian A. Walker, </li><li class="list-inline-item cited-by__entry__author">Meletios Athanasios Dimopoulos, </li><li class="list-inline-item cited-by__entry__author">Efstathios Kastritis, </li><li class="list-inline-item cited-by__entry__author">Julian Hess, </li><li class="list-inline-item cited-by__entry__author">Romanos Sklavenitis-Pistofidis, </li><li class="list-inline-item cited-by__entry__author">Chip Stewart, </li><li class="list-inline-item cited-by__entry__author">Gad Getz, </li><li class="list-inline-item cited-by__entry__author">Irene M. Ghobrial, </li></ul><span class="cited-by__entry__title">Genomic landscape of multiple myeloma and its precursor conditions, </span><span class="cited-by__entry__series-title">Nature Genetics, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41588-025-02196-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41588-025-02196-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41588-025-02196-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michelle Morcos-Sandino, </li><li class="list-inline-item cited-by__entry__author">Sofia Isabel Quezada-Ramírez, </li><li class="list-inline-item cited-by__entry__author">Andrés Gómez-De León, </li></ul><span class="cited-by__entry__title">Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries, </span><span class="cited-by__entry__series-title">Biomedicines, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1221), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/biomedicines13051221" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/biomedicines13051221</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/biomedicines13051221" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Carmelo Gurnari, </li><li class="list-inline-item cited-by__entry__author">Marie Robin, </li><li class="list-inline-item cited-by__entry__author">Lionel Adès, </li><li class="list-inline-item cited-by__entry__author">Mahmoud Aljurf, </li><li class="list-inline-item cited-by__entry__author">Antonio Almeida, </li><li class="list-inline-item cited-by__entry__author">Fernando Barroso Duarte, </li><li class="list-inline-item cited-by__entry__author">Elsa Bernard, </li><li class="list-inline-item cited-by__entry__author">Corey Cutler, </li><li class="list-inline-item cited-by__entry__author">Matteo Giovanni Della Porta, </li><li class="list-inline-item cited-by__entry__author">Theo De Witte, </li><li class="list-inline-item cited-by__entry__author">Amy DeZern, </li><li class="list-inline-item cited-by__entry__author">Joanna Drozd-Sokolowska, </li><li class="list-inline-item cited-by__entry__author">Eric Duncavage, </li><li class="list-inline-item cited-by__entry__author">Pierre Fenaux, </li><li class="list-inline-item cited-by__entry__author">Nico Gagelmann, </li><li class="list-inline-item cited-by__entry__author">Guillermo Garcia-Manero, </li><li class="list-inline-item cited-by__entry__author">Claudia Haferlach, </li><li class="list-inline-item cited-by__entry__author">Torsten Haferlach, </li><li class="list-inline-item cited-by__entry__author">Robert Hasserjian, </li><li class="list-inline-item cited-by__entry__author">Eva Hellström-Lindberg, </li><li class="list-inline-item cited-by__entry__author">Meagan Jacoby, </li><li class="list-inline-item cited-by__entry__author">Austin Kulasekararaj, </li><li class="list-inline-item cited-by__entry__author">R. Coleman Lindsley, </li><li class="list-inline-item cited-by__entry__author">Jaroslaw P. Maciejewski, </li><li class="list-inline-item cited-by__entry__author">Hideki Makishima, </li><li class="list-inline-item cited-by__entry__author">Luca Malcovati, </li><li class="list-inline-item cited-by__entry__author">Moshe Mittelman, </li><li class="list-inline-item cited-by__entry__author">Anders E. Myhre, </li><li class="list-inline-item cited-by__entry__author">Seishi Ogawa, </li><li class="list-inline-item cited-by__entry__author">Francesco Onida, </li><li class="list-inline-item cited-by__entry__author">Elli Papaemmanuil, </li><li class="list-inline-item cited-by__entry__author">Jakob Passweg, </li><li class="list-inline-item cited-by__entry__author">Uwe Platzbecker, </li><li class="list-inline-item cited-by__entry__author">Lisa Pleyer, </li><li class="list-inline-item cited-by__entry__author">Kavita Raj, </li><li class="list-inline-item cited-by__entry__author">Valeria Santini, </li><li class="list-inline-item cited-by__entry__author">Anna Sureda, </li><li class="list-inline-item cited-by__entry__author">Magnus Tobiasson, </li><li class="list-inline-item cited-by__entry__author">Maria Teresa Voso, </li><li class="list-inline-item cited-by__entry__author">Ibrahim Yakoub-Agha, </li><li class="list-inline-item cited-by__entry__author">Amer Zeidan, </li><li class="list-inline-item cited-by__entry__author">Matthew Walter, </li><li class="list-inline-item cited-by__entry__author">Nicolaus Kröger, </li><li class="list-inline-item cited-by__entry__author">Donal P. McLornan, </li><li class="list-inline-item cited-by__entry__author">Mario Cazzola, </li></ul><span class="cited-by__entry__title">Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT, </span><span class="cited-by__entry__series-title">Blood, </span><span class="cited-by__entry__volume"><strong>145</strong>, </span><span class="cited-by__entry__issue">18, </span><span class="cited-by__entry__page-range">(1987-2001), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1182/blood.2024025131" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1182/blood.2024025131</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1182/blood.2024025131" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rashmi Kanagal‐Shamanna, </li><li class="list-inline-item cited-by__entry__author">Anna Puiggros, </li><li class="list-inline-item cited-by__entry__author">Isabel Granada, </li><li class="list-inline-item cited-by__entry__author">Gordana Raca, </li><li class="list-inline-item cited-by__entry__author">Katrina Rack, </li><li class="list-inline-item cited-by__entry__author">Mar Mallo, </li><li class="list-inline-item cited-by__entry__author">Barbara Dewaele, </li><li class="list-inline-item cited-by__entry__author">Adam C. Smith, </li><li class="list-inline-item cited-by__entry__author">Yassmine Akkari, </li><li class="list-inline-item cited-by__entry__author">Brynn Levy, </li><li class="list-inline-item cited-by__entry__author">Robert P. Hasserjian, </li><li class="list-inline-item cited-by__entry__author">Adela Cisneros, </li><li class="list-inline-item cited-by__entry__author">Marta Salido, </li><li class="list-inline-item cited-by__entry__author">Guillermo Garcia‐Manero, </li><li class="list-inline-item cited-by__entry__author">Hui Yang, </li><li class="list-inline-item cited-by__entry__author">M. Anwar Iqbal, </li><li class="list-inline-item cited-by__entry__author">Ravindra Kolhe, </li><li class="list-inline-item cited-by__entry__author">Francesc Solé, </li><li class="list-inline-item cited-by__entry__author">Blanca Espinet, </li></ul><span class="cited-by__entry__title">Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping, </span><span class="cited-by__entry__series-title">American Journal of Hematology, </span><span class="cited-by__entry__volume"><strong>100</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1029-1048), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/ajh.27688" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/ajh.27688</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/ajh.27688" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sreejesh Sreedharanunni, </li><li class="list-inline-item cited-by__entry__author">Venus Thakur, </li><li class="list-inline-item cited-by__entry__author">Anand Balakrishnan, </li><li class="list-inline-item cited-by__entry__author">Man Updesh Singh Sachdeva, </li><li class="list-inline-item cited-by__entry__author">Prabhjot Kaur, </li><li class="list-inline-item cited-by__entry__author">Sudhanshi Raina, </li><li class="list-inline-item cited-by__entry__author">Manu Jamwal, </li><li class="list-inline-item cited-by__entry__author">Charanpreet Singh, </li><li class="list-inline-item cited-by__entry__author">Praveen Sharma, </li><li class="list-inline-item cited-by__entry__author">Nabhajit Mallik, </li><li class="list-inline-item cited-by__entry__author">Shano Naseem, </li><li class="list-inline-item cited-by__entry__author">Pulkit Rastogi, </li><li class="list-inline-item cited-by__entry__author">Arihant Jain, </li><li class="list-inline-item cited-by__entry__author">Gaurav Prakash, </li><li class="list-inline-item cited-by__entry__author">Alka Khadwal, </li><li class="list-inline-item cited-by__entry__author">Pankaj Malhotra, </li><li class="list-inline-item cited-by__entry__author">Reena Das, </li></ul><span class="cited-by__entry__title">Effective Utilization of a Customized Targeted Hybrid Capture RNA Sequencing in the Routine Molecular Categorization of Adolescent and Adult B-Lineage Acute Lymphoblastic Leukemia: A Real-World Experience, </span><span class="cited-by__entry__series-title">Molecular Diagnosis &amp; Therapy, </span><span class="cited-by__entry__volume"><strong>29</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(407-418), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40291-025-00779-5" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40291-025-00779-5</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40291-025-00779-5" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Angela Hamblin, </li><li class="list-inline-item cited-by__entry__author">Adele Timbs, </li></ul><span class="cited-by__entry__title">Application of next‐generation sequencing in haematology, </span><span class="cited-by__entry__series-title">Hoffbrand's Postgraduate Haematology, </span><span class="cited-by__entry__page-range">(106-120), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/9781119706687.ch8" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/9781119706687.ch8</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/9781119706687.ch8" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Marie-France Gagnon, </li><li class="list-inline-item cited-by__entry__author">Sahil S. Tonk, </li><li class="list-inline-item cited-by__entry__author">Benjamin Carcamo, </li><li class="list-inline-item cited-by__entry__author">Daniel Bustamante, </li><li class="list-inline-item cited-by__entry__author">Mariam Stein, </li><li class="list-inline-item cited-by__entry__author">Sarah H. Johnson, </li><li class="list-inline-item cited-by__entry__author">George Vasmatzis, </li><li class="list-inline-item cited-by__entry__author">Cinthya J. Zepeda-Mendoza, </li><li class="list-inline-item cited-by__entry__author">Patricia T. Greipp, </li><li class="list-inline-item cited-by__entry__author">Xinjie Xu, </li><li class="list-inline-item cited-by__entry__author">Rhett P. Ketterling, </li><li class="list-inline-item cited-by__entry__author">Jess F. Peterson, </li><li class="list-inline-item cited-by__entry__author">Wenjing Wang, </li><li class="list-inline-item cited-by__entry__author">Yajuan J. Liu, </li><li class="list-inline-item cited-by__entry__author">Vijay Tonk, </li><li class="list-inline-item cited-by__entry__author">Karen Tsuchiya, </li><li class="list-inline-item cited-by__entry__author">Santosh Chavali, </li><li class="list-inline-item cited-by__entry__author">Linda B. Baughn, </li></ul><span class="cited-by__entry__title">False positive NUP98 fluorescence in situ hybridization rearrangements in B-acute lymphoblastic leukemia, </span><span class="cited-by__entry__series-title">Cancer Genetics, </span><span class="cited-by__entry__volume"><strong>292-293</strong>, </span><span class="cited-by__entry__page-range">(57-64), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.cancergen.2025.01.006" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.cancergen.2025.01.006</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.cancergen.2025.01.006" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hiroyuki Takamori, </li><li class="list-inline-item cited-by__entry__author">Ying-Jung Huang, </li><li class="list-inline-item cited-by__entry__author">Hidehito Fukushima, </li><li class="list-inline-item cited-by__entry__author">Kazuaki Yokoyama, </li><li class="list-inline-item cited-by__entry__author">Ting-Yu Huang, </li><li class="list-inline-item cited-by__entry__author">Ming-Chung Kuo, </li><li class="list-inline-item cited-by__entry__author">Seishi Ogawa, </li><li class="list-inline-item cited-by__entry__author">Yasuhito Nannya, </li><li class="list-inline-item cited-by__entry__author">Lee-Yung Shih, </li></ul><span class="cited-by__entry__title">Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation, </span><span class="cited-by__entry__series-title">Leukemia, </span><span class="cited-by__entry__volume"><strong>39</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(1218-1227), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41375-025-02576-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41375-025-02576-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41375-025-02576-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Julie Choi, </li><li class="list-inline-item cited-by__entry__author">Zitian Tang, </li><li class="list-inline-item cited-by__entry__author">Wendy Dong, </li><li class="list-inline-item cited-by__entry__author">Jenna Ulibarri, </li><li class="list-inline-item cited-by__entry__author">Elvisa Mehinovic, </li><li class="list-inline-item cited-by__entry__author">Simone Thomas, </li><li class="list-inline-item cited-by__entry__author">Ahmet Höke, </li><li class="list-inline-item cited-by__entry__author">Sheng Chih Jin, </li></ul><span class="cited-by__entry__title">Unleashing the Power of Multiomics: Unraveling the Molecular Landscape of Peripheral Neuropathy, </span><span class="cited-by__entry__series-title">Annals of Clinical and Translational Neurology, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(674-685), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/acn3.70019" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/acn3.70019</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/acn3.70019" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-10%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2024534%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2024534" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2024534" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024534.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f1.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/1af70c22-5bd4-4565-8207-5f4096dce9b9/assets/images/large/nejmoa2024534_f1.jpg" height="2710" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Timeline of Whole-Genome Sequencing (WGS) Process and Study Design.</div><div class="notes"><div role="doc-footnote">Panel A shows the workflow and approximate processing time for each step of the rapid WGS method used for samples obtained from the study patients. As the first step in library construction, unfragmented DNA is cleaved and tagged for analysis in a process called tagmentation. Examples of the reports that were generated by this process are provided in Figures S1A and S1B in the <a href="#ap1">Supplementary Appendix</a>. Panel B shows the design of the study involving both retrospective and prospective cohorts of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The retrospective cohort included 146 samples obtained from individual patients selected to represent a broad range of cytogenetic and molecular features of AML and MDS. The prospective cohort included 117 unselected, consecutive samples obtained from patients with a known or suspected myeloid cancer for whom cytogenetic testing was requested at the study center. Seven of these patients ultimately received a diagnosis other than AML or MDS. QC denotes quality control.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f2.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/4df34424-43c7-4f02-86e4-27bb92eb1b69/assets/images/large/nejmoa2024534_f2.jpg" height="1264" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">A Comparison of WGS with Conventional Cytogenetic Analysis and Targeted Gene Sequencing.</div><div class="notes"><div role="doc-footnote">Panel A shows the sensitivity of WGS for the detection of recurrent structural variants (SVs) and copy-number alterations (CNAs) as compared with conventional cytogenetic analysis and for the detection of single-nucleotide variants (SNVs) and insertion–deletions (INDELs) as compared with high-coverage targeted gene sequencing. 𝙸 bars denote 95% confidence intervals. Panel B shows the identification and confirmation by WGS of 13 new recurrent SVs that were not detected by conventional cytogenetic analysis, as supported by orthogonal methods, including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) with sequencing of SV breakpoints, or detection of fusion transcripts in RNA-sequence (RNA-seq) data. Panel C shows the identification of 21 new CNAs in 14 patients; 12 of these alterations were confirmed by chromosomal microarray (CMA), FISH, or sequence-defined breakpoints. An additional 9 CNAs were identified by WGS only and could not be confirmed by CMA (in 6 patients) or confirmation was not attempted because of the size or abundance of the CNA event (in 3 patients). CNAs were also identified in 13 patients with ambiguous or inconclusive results on cytogenetic analysis. Additional details regarding these comparisons are provided in Tables S4 and S5 and Figure S2C in the <a href="#ap1">Supplementary Appendix</a>.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f3.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/83425336-c206-4394-88ac-99d8c6bc8fde/assets/images/large/nejmoa2024534_f3.jpg" height="2649" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Clinical Feasibility and Diagnostic Yield of WGS-Based Genomic Profiling in 117 Consecutive Patients.</div><div class="notes"><div role="doc-footnote">Panel A shows the time it took to process samples obtained from 117 consecutive patients with AML or MDS by means of WGS from April 2019 through February 2020. The median processing time for all study patients is indicated by the dashed horizontal black line. The height of each bar shows the total time in days for processing, starting from construction of the sequencing library and ending with completion of the automated final report for an individual patient sample. The duration of each individual step (as obtained from time stamps recorded in the information management system of the clinical laboratory) is indicated by the shaded bar segments and includes the duration of library generation and quality assessment, sequencing, and analysis and reporting. These times reflect the processing time plus waiting time before the next step. Longer turnaround times occurred because of delays between steps, rather than longer processing times. The dashed horizontal red lines show the recommended maximum turnaround time for FISH testing and conventional cytogenetic analysis, according to published recommendations,<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="core-body-ref-r21-1" href-manipulated="true" aria-label="Reference 21" data-to-manipulate="false">21</a></sup> although shorter turnaround times occur in many laboratories.</div><div role="doc-footnote">Panel B shows the yield of new WGS findings in samples obtained from 68 unselected, consecutive patients with AML. The top panel shows the cumulative number of patients with new genomic findings that were identified by WGS, as compared with conventional cytogenetic analysis or FISH, performed at the time of diagnosis, along with the cumulative number of patients with new events that changed the category of genetic risk group on the basis of established European Leukemia Network (ELN) guidelines.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="core-body-ref-r3-5" href-manipulated="true" aria-label="Reference 3" data-to-manipulate="false">3</a></sup> FISH testing included assays for <i>PML–RARA</i>, <i>CBFB–MYH11</i>, <i>RUNX1–RUNX1T1</i>, del(5q), and chromosome 7 deletion, according to recommendations<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r21" id="core-body-ref-r21-2" href-manipulated="true" data-to-manipulate="false">3,21</a></sup>; all testing was performed in samples obtained from 60 of 68 patients (88%), and subgroups of these assays were performed for the remaining patients. The results of ELN assignments to a genetic risk group by WGS, conventional cytogenetic analysis with FISH, and cytogenetic analysis alone are shown in the middle panel. The red asterisk indicates that the patient’s risk group was reclassified according to the WGS results, and the red arrow indicates that the conventional risk-group assignment was based on FISH results alone. Genomic events that were detected by WGS are shown in the bottom panel and are labeled as concordant with cytogenetic analysis, FISH, or target sequencing (in black), new findings made by WGS (in blue), and new findings that resulted in a change in the ELN genetic risk group (in red). The status regarding internal tandem duplication in <i>FLT3</i> (<i>FLT3</i>-ITD) and the allele ratio as determined by PCR were used for both conventional and WGS-based risk stratifications.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f4"><figure class="graphic"><a class="open-in-viewer" href="#f4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f4.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/a1337548-516d-4a33-91f6-ab0ca3649090/assets/images/large/nejmoa2024534_f4.jpg" height="2244" width="2640" aria-labelledby="f4" loading="lazy"></a><figcaption><div class="caption">Risk Assessment by WGS in Patients with AML, According to Existing Genetic Risk Groups.</div><div class="notes"><div role="doc-footnote">Panel A shows overall survival for 71 patients with AML who were treated with chemotherapy alone after remission, as stratified into established ELN genetic risk groups<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="core-body-ref-r3-9" href-manipulated="true" aria-label="Reference 3" data-to-manipulate="false">3</a></sup> on the basis of a combination of conventional cytogenetic analysis, FISH, and targeted gene sequencing. Panel B shows the same cohort as in Panel A with risk stratification according to WGS results. The ratio of the mutated <i>FLT3</i>-ITD allele to the wild-type allele, as determined by PCR, was used for both the conventional and WGS classifications; the presence or absence of the mutation was used when allele ratios were not available. Panel C shows the clinical outcomes for 27 patients for whom genetic risk could not be determined because of inconclusive, unsuccessful, or unknown results on cytogenetic analysis. The median survival in this cohort was 11.2 months (95% confidence interval [CI], 5.6 to 38.8). Panel D shows the stratification of the cohort in Panel C into established genetic risk groups with the use of WGS results, which predicted shorter overall survival for patients at adverse risk than for those at intermediate or favorable risk (not adverse) (age-adjusted hazard ratio for death for intermediate or favorable risk versus adverse risk, 0.29; 95% CI, 0.09 to 0.94). All P values were calculated with the use of a log-rank test for equal survival among the groups and were adjusted for multiple comparisons.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f4"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f4" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2024534/asset/1131647a-f938-4b9c-b31f-1966daa001c8/assets/images/large/nejmoa2024534_t1.jpg" height="3438" width="1652" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Retrospective Cohort</th><th class="txxr-borders">Prospective Cohort</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>All study patients</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">No. of patients</td><td class="xxxx-borders">146</td><td class="xxxr-borders">117</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients with successful cytogenetic analysis<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">126</td><td class="xxxr-borders shading">109</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Patients with AML</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">107</td><td class="xxxr-borders shading">68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean age — yr</td><td class="xxxx-borders">53.7</td><td class="xxxr-borders">60.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">47 (44)</td><td class="xxxr-borders shading">30 (44)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">ELN genetic risk group — no. of patients<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Acute promyelocytic leukemia with t(15;17)(q22;q21)/<i>PML–RARA</i></td><td class="xxxx-borders shading">5</td><td class="xxxr-borders shading">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Favorable risk</td><td class="xxxx-borders">28</td><td class="xxxr-borders">19</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">t(8;21)(q22;q22.1)/<i>RUNX1–RUNX1T1</i></td><td class="xxxx-borders shading">6</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/<i>CBFB–MYH11</i></td><td class="xxxx-borders">11</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left"><i>NPM1c</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD<sup>low</sup><a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">15</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Biallelic <i>CEBPA</i></td><td class="xxxx-borders">3</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Intermediate risk</td><td class="xxxx-borders shading">22</td><td class="xxxr-borders shading">10</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">t(9;11)(p21;q23)/<i>KMT2A–MLLT3</i></td><td class="xxxx-borders">1</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wild-type <i>NPM1</i> without <i>FLT3</i>-ITD or with <i>FLT3</i>-ITD<sup>low</sup><a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">11</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left"><i>NPM1c</i> with <i>FLT3</i>-ITD or <i>FLT3</i>-ITD<sup>high</sup><a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">7</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other risk not favorable or adverse</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Adverse</td><td class="xxxx-borders">20</td><td class="xxxr-borders">27</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Complex karyotype or mutated <i>TP53</i></td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">13</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">t(v;11q23.3)/<i>KMT2A</i> rearranged</td><td class="xxxx-borders">3</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">inv(3)(q21.3q26.2) or t(3;3)(q21.3;26.2)/<i>GATA2–MECOM</i></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Chromosome 5 deletion, del(5q), or chromosome 7 deletion</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wild-type <i>NPM1</i> with <i>FLT3</i>-ITD or <i>FLT3</i>-ITD<sup>high</sup><a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Mutated <i>RUNX1</i> or <i>ASXL1</i></td><td class="xxxx-borders">0</td><td class="xxxr-borders">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Undetermined<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">32</td><td class="xxxr-borders shading">7</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Patients with MDS</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">No. of patients</td><td class="xxxx-borders shading">39</td><td class="xxxr-borders shading">42</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean age — yr</td><td class="xxxx-borders">59.8</td><td class="xxxr-borders">68.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">17 (44)</td><td class="xxxr-borders shading">12 (29)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">IPSS-R risk category — no. of patients<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very good</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Good</td><td class="xxxx-borders">11</td><td class="xxxr-borders">17</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">10</td><td class="xxxr-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Poor</td><td class="xxxx-borders">4</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Very poor</td><td class="xxxx-borders shading">13</td><td class="xxxr-borders shading">6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Undetermined<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxr-borders">9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left"><b>Patients with other hematologic cancer</b><a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">NA</td><td class="xxxr-borders shading">7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Acute lymphoblastic leukemia</td><td class="xxxx-borders">NA</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03 shading" data-xml-align="left">Other form</td><td class="xbxx-borders shading">NA</td><td class="xbxr-borders shading">2</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">AML denotes acute myeloid leukemia, MDS myelodysplastic syndromes, and NA not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Successful cytogenetic analysis was defined as the analysis of at least three metaphase cells from cultures prepared from tumor specimens with the use of conventional cytogenetic methods.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Risk groups for patients with AML according to the European Leukemia Network (ELN) guidelines are listed by their defining features and were assigned on the basis of results from conventional cytogenetic analysis; results from FISH (performed at diagnosis) for <i>PML–RARA</i>, <i>CBFB–MYH11</i>, <i>RUNX1–RUNX1T1</i>, del(5q), and chromosome 7; results from polymerase chain reaction (PCR) for <i>FLT3</i>-ITD; and results from targeted sequencing. At least 20 metaphase cells were required to identify a normal karyotype. Nine patients with AML were assigned to a risk group on the basis of positive results on FISH for either <i>PML–RARA</i> (1 patient), <i>CBFB–MYH11</i> (4 patients), or del(5q) (4 patients). Three patients were classified as having intermediate risk on the basis of cytogenetic analysis and testing for <i>NPM1c</i> and <i>FLT3</i>-ITD alone because targeted gene sequencing was not performed.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true"><i>FLT3</i>-ITD status was obtained from clinical testing by means of PCR and capillary electrophoresis. High and low allele ratios were determined on the basis of the established cutoff of 0.5 when available (in 7 of 30 patients with positive results for <i>FLT3</i>-ITD); otherwise <i>FLT3</i>-ITD status was treated as a binary variable.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The category of undetermined risk indicates that risk could not be classified because of inconclusive or unsuccessful results on cytogenetic analysis (i.e., no metaphase cells were available for analysis or a normal karyotype was observed in &lt;20 cells), as described previously.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><div class="label">‖</div></a><div id="core-t1fn6" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg">Risk categories are those used in the International Prognostic Scoring System–Revised (IPSS-R). The retrospective cohort also included 2 patients with a t(6;9) translocation, which is risk-defining in AML but has no prognostic significance in MDS. Details are provided in Table S3 in the </a><a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Whole-genome sequencing was performed on samples obtained from consecutive patients, some of whom subsequently received a diagnosis other than AML or MDS, including acute lymphoblastic leukemia, paroxysmal nocturnal hemoglobinuria, and no pathological diagnosis. Three of the patients with acute lymphoblastic leukemia had positive results for <i>BCR–ABL1</i>, which was detected by whole-genome sequencing.</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Study Patients.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2024534_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2024534</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Nangalia J, Campbell PJ. Genome sequencing during a patient’s journey through cancer. <em>N Engl J Med</em> 2019;381:2145-2156.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMra1910138&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31774959/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000501362000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genome+sequencing+during+a+patient%E2%80%99s+journey+through+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2145-2156&amp;doi=10.1056%2FNEJMra1910138&amp;pmid=31774959" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. <em>JAMA</em> 2011;305:1577-1584.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2011.497" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21505136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000289683000027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+whole-genome+sequencing+to+diagnose+a+cryptic+fusion+oncogene.&amp;publication_year=2011&amp;journal=JAMA&amp;pages=1577-1584&amp;doi=10.1001%2Fjama.2011.497&amp;pmid=21505136" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <em>Blood</em> 2017;129:424-447.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-08-733196" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27895058/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396531400009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+management+of+AML+in+adults%3A+2017+ELN+recommendations+from+an+international+expert+panel.&amp;publication_year=2017&amp;journal=Blood&amp;pages=424-447&amp;doi=10.1182%2Fblood-2016-08-733196&amp;pmid=27895058" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic mutations with clinical outcomes </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] risk stratification in patients with AML. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] workup for patients with AML or MDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] Network (ELN) or IPSS-R risk categories. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r3-5"><i aria-hidden="true" class="icon-return"></i><span>e [...] European Leukemia Network (ELN) guidelines. </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r3-6"><i aria-hidden="true" class="icon-return"></i><span>f [...] 7 deletion, according to recommendations </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] clinical results from a standard FISH panel </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] on the basis of established guidelines </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f4" role="menuitem" data-target="#fv-body-ref-r3-9"><i aria-hidden="true" class="icon-return"></i><span>i [...] into established ELN genetic risk groups </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. <em>N Engl J Med</em> 2008;358:1909-1918.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa074306&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18450602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000255387900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia.&amp;publication_year=2008&amp;journal=N+Engl+J+Med&amp;pages=1909-1918&amp;doi=10.1056%2FNEJMoa074306&amp;pmid=18450602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. <em>Blood</em> 2005;106:3733-3739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-06-2248" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16076867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000233662400018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nucleophosmin+gene+mutations+are+predictors+of+favorable+prognosis+in+acute+myelogenous+leukemia+with+a+normal+karyotype.&amp;publication_year=2005&amp;journal=Blood&amp;pages=3733-3739&amp;doi=10.1182%2Fblood-2005-06-2248&amp;pmid=16076867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. <em>N Engl J Med</em> 2016;375:2023-2036.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1605949&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27959731/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388464300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=TP53+and+decitabine+in+acute+myeloid+leukemia+and+myelodysplastic+syndromes.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=2023-2036&amp;doi=10.1056%2FNEJMoa1605949&amp;pmid=27959731" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. <em>N Engl J Med</em> 2016;374:2209-2221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1516192&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27276561/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377920500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+classification+and+prognosis+in+acute+myeloid+leukemia.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=2209-2221&amp;doi=10.1056%2FNEJMoa1516192&amp;pmid=27276561" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] genetic mutations with clinical outcomes </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] occurs in up to 20% of patients with AML. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network. NCCN guidelines for patients: acute myeloid leukemia (<a href="https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf">https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=National+Comprehensive+Cancer+Network.+NCCN+guidelines+for+patients%3A+acute+myeloid+leukemia+%28https%3A%2F%2Fwww.nccn.org%2Fpatients%2Fguidelines%2Fcontent%2FPDF%2Faml-patient.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk stratification in patients with AML. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] workup for patients with AML or MDS. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] on the basis of established guidelines </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. <em>Blood</em> 2012;120:2454-2465.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-03-420489" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22740453/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000309044600019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+international+prognostic+scoring+system+for+myelodysplastic+syndromes.&amp;publication_year=2012&amp;journal=Blood&amp;pages=2454-2465&amp;doi=10.1182%2Fblood-2012-03-420489&amp;pmid=22740453" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] System–Revised (IPSS-R) in such patients. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Network (ELN) or IPSS-R risk categories. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. <em>Nature</em> 2008;456:66-72.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature07485" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18987736/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000260674000041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+sequencing+of+a+cytogenetically+normal+acute+myeloid+leukaemia+genome.&amp;publication_year=2008&amp;journal=Nature&amp;pages=66-72&amp;doi=10.1038%2Fnature07485&amp;pmid=18987736" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. <em>N Engl J Med</em> 2013;368:2059-2074.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1301689&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23634996/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000319574200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+and+epigenomic+landscapes+of+adult+de+novo+acute+myeloid+leukemia.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=2059-2074&amp;doi=10.1056%2FNEJMoa1301689&amp;pmid=23634996" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] such sequencing to research studies, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] variants have been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Mardis ER. The $1,000 genome, the $100,000 analysis? <em>Genome Med</em> 2010;2:84-84.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/gm205" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21114804/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208627100084" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+%241%2C000+genome%2C+the+%24100%2C000+analysis%3F&amp;publication_year=2010&amp;journal=Genome+Med&amp;pages=84-84&amp;doi=10.1186%2Fgm205&amp;pmid=21114804" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. <em>N Engl J Med</em> 2009;361:1058-1066.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_14_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa0903840&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19657110/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269659400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recurring+mutations+found+by+sequencing+an+acute+myeloid+leukemia+genome.&amp;publication_year=2009&amp;journal=N+Engl+J+Med&amp;pages=1058-1066&amp;doi=10.1056%2FNEJMoa0903840&amp;pmid=19657110" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. <em>Cell</em> 2012;150:264-278.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2012.06.023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22817890/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000306595700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+origin+and+evolution+of+mutations+in+acute+myeloid+leukemia.&amp;publication_year=2012&amp;journal=Cell&amp;pages=264-278&amp;doi=10.1016%2Fj.cell.2012.06.023&amp;pmid=22817890" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Bolouri H, Farrar JE, Triche T Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. <em>Nat Med</em> 2018;24:103-112.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm.4439" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29227476/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422965900016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+molecular+landscape+of+pediatric+acute+myeloid+leukemia+reveals+recurrent+structural+alterations+and+age-specific+mutational+interactions.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=103-112&amp;doi=10.1038%2Fnm.4439&amp;pmid=29227476" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Rusch M, Nakitandwe J, Shurtleff S, et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <em>Nat Commun</em> 2018;9:3962-3962.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-018-06485-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30262806/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445820300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+cancer+genomic+profiling+by+three-platform+sequencing+of+whole+genome%2C+whole+exome+and+transcriptome.&amp;publication_year=2018&amp;journal=Nat+Commun&amp;pages=3962-3962&amp;doi=10.1038%2Fs41467-018-06485-7&amp;pmid=30262806" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Duncavage EJ, Jacoby MA, Chang GS, et al. Mutation clearance after transplantation for myelodysplastic syndrome. <em>N Engl J Med</em> 2018;379:1028-1041.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2024534&amp;key=10.1056%2FNEJMoa1804714&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30207916/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444501600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mutation+clearance+after+transplantation+for+myelodysplastic+syndrome.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=1028-1041&amp;doi=10.1056%2FNEJMoa1804714&amp;pmid=30207916" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Huret J-L, Ahmad M, Arsaban M, et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. <em>Nucleic Acids Res</em> 2013;41:(D1):D920-D924.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gks1082" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23161685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000312893300130" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atlas+of+genetics+and+cytogenetics+in+oncology+and+haematology+in+2013.&amp;publication_year=2013&amp;journal=Nucleic+Acids+Res&amp;pages=D920-D924&amp;doi=10.1093%2Fnar%2Fgks1082&amp;pmid=23161685" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <em>Blood</em> 2016;127:2391-2405.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-03-643544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27069254/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378333900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia.&amp;publication_year=2016&amp;journal=Blood&amp;pages=2391-2405&amp;doi=10.1182%2Fblood-2016-03-643544&amp;pmid=27069254" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Griffith M, Miller CA, Griffith OL, et al. Optimizing cancer genome sequencing and analysis. <em>Cell Syst</em> 2015;1:210-223.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cels.2015.08.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26645048/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000209925900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+cancer+genome+sequencing+and+analysis.&amp;publication_year=2015&amp;journal=Cell+Syst&amp;pages=210-223&amp;doi=10.1016%2Fj.cels.2015.08.015&amp;pmid=26645048" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. <em>Leukemia</em> 2019;33:1851-1867.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-019-0378-z" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30696948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479118400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=European+recommendations+and+quality+assurance+for+cytogenomic+analysis+of+haematological+neoplasms.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=1851-1867&amp;doi=10.1038%2Fs41375-019-0378-z&amp;pmid=30696948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>a [...] according to published recommendations, </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r21-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] 7 deletion, according to recommendations </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] clinical results from a standard FISH panel </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <em>Blood</em> 2002;100:4325-4336.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2002-03-0772" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12393746/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000179759800015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pretreatment+cytogenetic+abnormalities+are+predictive+of+induction+success%2C+cumulative+incidence+of+relapse%2C+and+overall+survival+in+adult+patients+with+de+novo+acute+myeloid+leukemia%3A+results+from+Cancer+and+Leukemia+Group+B+%28CALGB+8461%29.&amp;publication_year=2002&amp;journal=Blood&amp;pages=4325-4336&amp;doi=10.1182%2Fblood-2002-03-0772&amp;pmid=12393746" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Lazarevic V, Hörstedt A-S, Johansson B, et al. Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia. <em>Eur J Haematol</em> 2015;94:419-423.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/ejh.12446" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25200361/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352633000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Failure+matters%3A+unsuccessful+cytogenetics+and+unperformed+cytogenetics+are+associated+with+a+poor+prognosis+in+a+population-based+series+of+acute+myeloid+leukaemia.&amp;publication_year=2015&amp;journal=Eur+J+Haematol&amp;pages=419-423&amp;doi=10.1111%2Fejh.12446&amp;pmid=25200361" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <em>Br J Haematol</em> 2014;164:245-250.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12625" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24383844/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000329178100011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Unsuccessful+diagnostic+cytogenetic+analysis+is+a+poor+prognostic+feature+in+acute+myeloid+leukaemia.&amp;publication_year=2014&amp;journal=Br+J+Haematol&amp;pages=245-250&amp;doi=10.1111%2Fbjh.12625&amp;pmid=24383844" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Wetterstrand KA. DNA sequencing costs: data from the NHGRI Genome Sequencing Program (GSP). <em>National Human Genome Research Institute</em>, 2020 (<a href="https://www.genome.gov/sequencingcostsdata">www.genome.gov/sequencingcostsdata</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+sequencing+costs%3A+data+from+the+NHGRI+Genome+Sequencing+Program+%28GSP%29.&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] decrease in the price of sequencing </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] costs are lower (approximately $7 per Gbp), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Cressman S, Karsan A, Hogge DE, et al. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <em>Br J Haematol</em> 2016;174:526-535.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.14076" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27098559/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000383774500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Economic+impact+of+genomic+diagnostics+for+intermediate-risk+acute+myeloid+leukaemia.&amp;publication_year=2016&amp;journal=Br+J+Haematol&amp;pages=526-535&amp;doi=10.1111%2Fbjh.14076&amp;pmid=27098559" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 23, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2106014" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Genome Sequencing in Myeloid Cancers</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Rhinebeck, New York</span></div><div><span>Geriatrics</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887326/geriatrician-rhinebeck-ny-90-minutes-north-of-nyc-/?query=fjwp&amp;rid=12925">Geriatrician, Rhinebeck, NY (90 minutes North of NYC)</a></div></div><div class="nejm-widget_item"><div><span> Bay Shore, New York</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/823687/primary-care-physician-bay-shore-ny-/?query=fjwp&amp;rid=3059">Primary Care Physician- Bay Shore, NY </a></div></div><div class="nejm-widget_item"><div><span> Jefferson City, Missouri</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890180/become-a-family-medicine-physician-in-historic-jefferson-city-mo-/?query=fjwf&amp;rid=196467">Become a Family Medicine Physician in historic Jefferson City, MO!</a></div></div><div class="nejm-widget_item"><div><span> Colorado</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890699/caon-city-colorado-snf-ltc-group-offering-flexible-schedule-no-call/?query=fjwf&amp;rid=5127">Caon City, Colorado SNF/ LTC Group Offering Flexible Schedule, No Call</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880959/general-otolaryngologist-reliant-medical-group-full-time/?query=fjwf&amp;rid=220874">General  Otolaryngologist - Reliant Medical Group - Full Time</a></div></div><div class="nejm-widget_item"><div><span> Vancouver, Washington State</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888049/family-medicine-physician/?query=fjwf&amp;rid=14710">Family Medicine Physician</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024534&amp;pubId=41289735&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d671aab38a80fe-LAX">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d671aab38a80fe-LAX"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d671aab38a80fe-LAX"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$431870946$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$431870946$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$431870946$--></div></div><div class="mlt-body"><!--?lit$431870946$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$431870946$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$431870946$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$431870946$-->Jan 09, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408941?query=recirc_Semantic" target="_self">Clearance of Driver Mutations after Transplantation for Myelofibrosis</a></div><div class="mlt-article-authors"><!--?lit$431870946$-->N. Gagelmann and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$431870946$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$431870946$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$431870946$-->Jun 12, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008?query=recirc_Semantic" target="_self">Molecular International Prognostic Scoring System for Myelodysplastic Syndromes</a></div><div class="mlt-article-authors"><!--?lit$431870946$-->E. Bernard and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$431870946$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$431870946$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$431870946$-->Oct 01, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra1904794?query=recirc_Semantic" target="_self">Myelodysplastic Syndromes</a></div><div class="mlt-article-authors"><!--?lit$431870946$-->M. Cazzola</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$431870946$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$431870946$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$431870946$-->Apr 24, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2504775?query=recirc_Semantic" target="_self">Clonal Hematopoiesis as a Driver of Solid Tumors</a></div><div class="mlt-article-authors"><!--?lit$431870946$-->L.D. Weeks and B.L. Ebert</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$431870946$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$431870946$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$431870946$-->Oct 10, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2405541?query=recirc_Semantic" target="_self">Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy</a></div><div class="mlt-article-authors"><!--?lit$431870946$-->C.N. Duncan and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2024534?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2024534" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2024534.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2024534"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2009965" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Risdiplam in Type 1 Spinal Muscular Atrophy</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2005756" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Spermatogonium-Derived Complete Hydatidiform Mole</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f1.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/1af70c22-5bd4-4565-8207-5f4096dce9b9/assets/images/large/nejmoa2024534_f1.jpg" height="2710" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Timeline of Whole-Genome Sequencing (WGS) Process and Study Design.</div><div class="notes"><div role="doc-footnote">Panel A shows the workflow and approximate processing time for each step of the rapid WGS method used for samples obtained from the study patients. As the first step in library construction, unfragmented DNA is cleaved and tagged for analysis in a process called tagmentation. Examples of the reports that were generated by this process are provided in Figures S1A and S1B in the <a href="#ap1">Supplementary Appendix</a>. Panel B shows the design of the study involving both retrospective and prospective cohorts of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The retrospective cohort included 146 samples obtained from individual patients selected to represent a broad range of cytogenetic and molecular features of AML and MDS. The prospective cohort included 117 unselected, consecutive samples obtained from patients with a known or suspected myeloid cancer for whom cytogenetic testing was requested at the study center. Seven of these patients ultimately received a diagnosis other than AML or MDS. QC denotes quality control.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f2.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/4df34424-43c7-4f02-86e4-27bb92eb1b69/assets/images/large/nejmoa2024534_f2.jpg" height="1264" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">A Comparison of WGS with Conventional Cytogenetic Analysis and Targeted Gene Sequencing.</div><div class="notes"><div role="doc-footnote">Panel A shows the sensitivity of WGS for the detection of recurrent structural variants (SVs) and copy-number alterations (CNAs) as compared with conventional cytogenetic analysis and for the detection of single-nucleotide variants (SNVs) and insertion–deletions (INDELs) as compared with high-coverage targeted gene sequencing. 𝙸 bars denote 95% confidence intervals. Panel B shows the identification and confirmation by WGS of 13 new recurrent SVs that were not detected by conventional cytogenetic analysis, as supported by orthogonal methods, including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) with sequencing of SV breakpoints, or detection of fusion transcripts in RNA-sequence (RNA-seq) data. Panel C shows the identification of 21 new CNAs in 14 patients; 12 of these alterations were confirmed by chromosomal microarray (CMA), FISH, or sequence-defined breakpoints. An additional 9 CNAs were identified by WGS only and could not be confirmed by CMA (in 6 patients) or confirmation was not attempted because of the size or abundance of the CNA event (in 3 patients). CNAs were also identified in 13 patients with ambiguous or inconclusive results on cytogenetic analysis. Additional details regarding these comparisons are provided in Tables S4 and S5 and Figure S2C in the <a href="#ap1">Supplementary Appendix</a>.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f3.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/83425336-c206-4394-88ac-99d8c6bc8fde/assets/images/large/nejmoa2024534_f3.jpg" height="2649" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Clinical Feasibility and Diagnostic Yield of WGS-Based Genomic Profiling in 117 Consecutive Patients.</div><div class="notes"><div role="doc-footnote">Panel A shows the time it took to process samples obtained from 117 consecutive patients with AML or MDS by means of WGS from April 2019 through February 2020. The median processing time for all study patients is indicated by the dashed horizontal black line. The height of each bar shows the total time in days for processing, starting from construction of the sequencing library and ending with completion of the automated final report for an individual patient sample. The duration of each individual step (as obtained from time stamps recorded in the information management system of the clinical laboratory) is indicated by the shaded bar segments and includes the duration of library generation and quality assessment, sequencing, and analysis and reporting. These times reflect the processing time plus waiting time before the next step. Longer turnaround times occurred because of delays between steps, rather than longer processing times. The dashed horizontal red lines show the recommended maximum turnaround time for FISH testing and conventional cytogenetic analysis, according to published recommendations,<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="fv-body-ref-r21-1" href-manipulated="true" aria-label="Reference 21" data-to-manipulate="false">21</a></sup> although shorter turnaround times occur in many laboratories.</div><div role="doc-footnote">Panel B shows the yield of new WGS findings in samples obtained from 68 unselected, consecutive patients with AML. The top panel shows the cumulative number of patients with new genomic findings that were identified by WGS, as compared with conventional cytogenetic analysis or FISH, performed at the time of diagnosis, along with the cumulative number of patients with new events that changed the category of genetic risk group on the basis of established European Leukemia Network (ELN) guidelines.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="fv-body-ref-r3-5" href-manipulated="true" aria-label="Reference 3" data-to-manipulate="false">3</a></sup> FISH testing included assays for <i>PML–RARA</i>, <i>CBFB–MYH11</i>, <i>RUNX1–RUNX1T1</i>, del(5q), and chromosome 7 deletion, according to recommendations<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r21" id="fv-body-ref-r21-2" href-manipulated="true" data-to-manipulate="false">3,21</a></sup>; all testing was performed in samples obtained from 60 of 68 patients (88%), and subgroups of these assays were performed for the remaining patients. The results of ELN assignments to a genetic risk group by WGS, conventional cytogenetic analysis with FISH, and cytogenetic analysis alone are shown in the middle panel. The red asterisk indicates that the patient’s risk group was reclassified according to the WGS results, and the red arrow indicates that the conventional risk-group assignment was based on FISH results alone. Genomic events that were detected by WGS are shown in the bottom panel and are labeled as concordant with cytogenetic analysis, FISH, or target sequencing (in black), new findings made by WGS (in blue), and new findings that resulted in a change in the ELN genetic risk group (in red). The status regarding internal tandem duplication in <i>FLT3</i> (<i>FLT3</i>-ITD) and the allele ratio as determined by PCR were used for both conventional and WGS-based risk stratifications.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f4" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2024534_f4.jpg"><img src="/cms/10.1056/NEJMoa2024534/asset/a1337548-516d-4a33-91f6-ab0ca3649090/assets/images/large/nejmoa2024534_f4.jpg" height="2244" width="2640" aria-labelledby="f4" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 4</div><div class="fv__item__description"><figcaption><div class="caption">Risk Assessment by WGS in Patients with AML, According to Existing Genetic Risk Groups.</div><div class="notes"><div role="doc-footnote">Panel A shows overall survival for 71 patients with AML who were treated with chemotherapy alone after remission, as stratified into established ELN genetic risk groups<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="fv-body-ref-r3-9" href-manipulated="true" aria-label="Reference 3" data-to-manipulate="false">3</a></sup> on the basis of a combination of conventional cytogenetic analysis, FISH, and targeted gene sequencing. Panel B shows the same cohort as in Panel A with risk stratification according to WGS results. The ratio of the mutated <i>FLT3</i>-ITD allele to the wild-type allele, as determined by PCR, was used for both the conventional and WGS classifications; the presence or absence of the mutation was used when allele ratios were not available. Panel C shows the clinical outcomes for 27 patients for whom genetic risk could not be determined because of inconclusive, unsuccessful, or unknown results on cytogenetic analysis. The median survival in this cohort was 11.2 months (95% confidence interval [CI], 5.6 to 38.8). Panel D shows the stratification of the cohort in Panel C into established genetic risk groups with the use of WGS results, which predicted shorter overall survival for patients at adverse risk than for those at intermediate or favorable risk (not adverse) (age-adjusted hazard ratio for death for intermediate or favorable risk versus adverse risk, 0.29; 95% CI, 0.09 to 0.94). All P values were calculated with the use of a log-rank test for equal survival among the groups and were adjusted for multiple comparisons.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Study Patients.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/10" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 10</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 11, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2033130" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">ACTIV-3/TICO LY-CoV555 Study Group</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 11, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2005756" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Spermatogonium-Derived Complete Hydatidiform Mole</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. Usui and M. Shozu</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Mar 11, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2009965" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Risdiplam in Type 1 Spinal Muscular Atrophy</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Baranello and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2024534%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024534&amp;pubId=41289735&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2024534%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2024534&amp;pubId=41289735&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id006197678152736075" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d671aab38a80fe-LAX" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d671aab38a80fe-LAX" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d671aab38a80fe-LAX"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d671aab38a80fe-LAX"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d671aab38a80fe-LAX"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d671aab38a80fe-LAX"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d671aab38a80fe-LAX">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d671aab38a80fe-LAX">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d671aab38a80fe-LAX"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d671aab38a80fe-LAX"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d671aaaeff80fe',t:'MTc0OTUzMzA4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d671aaaeff80fe&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-transactionid="9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" id="captureIFrame_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" target="captureIFrame_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="capture_screen"><input id="capture_signIn_js_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="js_version"><input id="capture_signIn_transactionId_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" type="hidden" class="capture_transactionId_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="capture_transactionId"><input id="capture_signIn_form_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="form"><input id="capture_signIn_flow_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="flow"><input id="capture_signIn_client_id_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="client_id"><input id="capture_signIn_redirect_uri_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="redirect_uri"><input id="capture_signIn_response_type_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="response_type"><input id="capture_signIn_flow_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="flow_version"><input id="capture_signIn_settings_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="settings_version"><input id="capture_signIn_locale_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="locale"><input id="capture_signIn_recaptcha_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_9gw62yzvt9hbembnm8ndszcajay962vx7gb4nry3" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><rzh-qngknsekdknd></rzh-qngknsekdknd><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2024534?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>